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ABSTRACT 
Introduction 
End stage kidney disease (ESKD) accounts for 5-10 million deaths annually worldwide.  
The current treatment modalities for ESKD include dialysis, transplant and supportive 
care.  The leading cause of death for people with ESKD is cardiovascular disease (CVD). 
CVD is a collective term for disease affecting the heart and blood vessels including 
coronary, cerebral and peripheral blood vessels.   CVD causes significant morbidity and 
has a substantial impact on quality of life for people with ESKD.  Improving 
cardiovascular outcomes for people living with ESKD is a priority.   
 
The escalating incidence of chronic kidney disease, its progression to ESKD and the 
high burden of cardiovascular disease has generated an increasing amount of research 
in the ESKD population. The ESKD population have previously been under-represented 
in clinical trials and current trials in ESKD have infrequently and inconsistently reported 
CVD outcomes.  It is important to standardise outcomes used in research. When 
outcome reporting is standardised it enables comparisons of findings across trials, 
populations and eras.  It is important that the outcomes reflect patient priorities and 
are relevant to patients and clinicians for use in shared decision making.   
 
The Standardised Outcomes in Nephrology Group (SONG) is an international initiative 
to establish a set of core outcomes and outcome measures across the spectrum of 
kidney disease for trials and other forms of research. The SONG-Haemodialysis (SONG - 
HD) initiative is developing a core outcome set for use in haemodialysis.  As part of 
SONG-HD, CVD (as well as fatigue, vascular access and mortality) has been identified as 
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important to all stakeholders and included in the core outcome set for haemodialysis.  
This requires appropriate measures of CVD to be identified and used.   
 
The first aim of this thesis was to achieve consensus on a CVD outcome measure for 
use in haemodialysis trials. In approaching this goal I first needed to ascertain the 
current use of cardiovascular outcomes (Chapter 2) and then determine which ones 
were important to all stakeholders (Chapter 3).  Consensus over which is the most 
appropriate measure of CVD for use in trials in people on haemodialysis (Chapter 4) 
will allow improved standardisation of cardiovascular outcome reporting, reducing 
research wastage and will propel forward cardiovascular research to improve 
morbidity and mortality in this high risk population. 
 
The second aim of this thesis was to further examine some of the prioritised outcomes 
and to review the patterns and risks of CVD in the ESKD population.  The magnitude of 
risk for cardiac events and cardiac deaths in people with ESKD relative to the general 
population and the changes over time are not well described.  I hypothesised that the 
magnitude of risk remained high in the ESKD population and that epidemiological 
improvements seen in CVD outcomes in the general population have not been 
mirrored in the ESKD population (Chapters 5 and 6).   CVD and more specifically 
cerebrovascular disease can lead to significant cognitive impairment which has a 
substantial impact on the ability of ESKD patients to understand their disease, 
interpret education and be involved in shared decision making.  The patterns of 
cognitive deficit in the ESKD population are not well understood and I hypothesised 
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that cognitive deficits in the ESKD population may be different to those found in the 
general population and may differ by modality of renal replacement therapy.  
 
Standardising CVD outcomes, examining the epidemiology of CVD in ESKD and 
comparing the trends and patterns to the general population can drive hypotheses 
into potential causative mechanisms and new treatments.  I present this thesis as a 
hybrid of published work, work currently under peer review for publication and work 
submitted for publication on the theme of priorities and outcomes in ESKD.   
 
Cardiovascular outcomes reported in contemporary haemodialysis trials (Chapter 2) 
There are currently no universally agreed cardiovascular outcomes for trials conducted 
specifically in the haemodialysis population. To ascertain current practice, as part of 
the SONG-HD initiative, I undertook a systematic search of published or in progress, 
randomised control trials in adults on haemodialysis, from 2011 to 2017, which 
reported at least one cardiovascular outcome. I identified and included 174 trials 
involving 148,730 participants.  I found that trials reporting cardiovascular outcomes in 
haemodialysis patients are usually of short duration (median 3 to 6 months) and are 
small (59% of trials have <100 participants). I extracted 1743 definitions of outcomes 
and classified the outcomes into 236 measures (e.g. troponin) and then distilled these 
into 26 outcome groups (e.g. cardiac biomarker). Of the 26 outcome groups, 15 (58%) 
were clinical, 10 (38%) were surrogate outcomes and only one (4%), was a patient-
reported outcome – pain. Nearly a third of trials (51[29%]) used a composite outcome 
and of those 51 trials there were 50 unique composite combinations illustrating the 
current difficulty in comparing composite outcomes across trials.  Currently reported 
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cardiovascular outcomes are very heterogeneous and are often surrogates or 
composites which may not reflect outcomes that are meaningful to patients nor help 
clinicians in supporting decision making.  
 
International survey to identify important cardiovascular outcomes (Chapter 3) 
A critical component of developing a proposed outcome is that the outcome is 
deemed meaningful and relevant to all stakeholders.  The aim of this study was to 
identify the priorities of patients/caregivers and health professionals for cardiovascular 
disease outcomes to be reported in all haemodialysis trials.  I performed an 
international, online survey (available in English and Chinese languages).  Participants 
were asked to rate the importance of ten cardiovascular outcomes (derived from the 
systematic review described in Chapter 2) on a 9-point Likert Scale, with a score of 7-9 
being critically important.  To determine relative importance participants also 
completed a best-worst scale. Likert means, medians and proportions and best-worst 
preference scores were calculated for each outcome.  Participants included 127 (19%) 
patients/caregivers and 549 (81%) health professionals from 53 countries; of whom 
530 (78%) completed the survey in English and 146 (22%) in Chinese.  All but one CV 
outcome (valve replacement) was rated as critically important (Likert 7-9) by all 
participants. Patients/caregivers ranked sudden cardiac death, heart attack, stroke and 
heart failure as the most important outcomes with mean preference scores and 95% CI 
of 6.2 (4.8-7.5), 5.9 (4.6-7.2), 5.3 (4.0-6.6) and 4.9 (3.6-6.3).  The same four outcomes 
were ranked most highly by health professionals.  We identified five themes for 
prioritisation of outcomes: clinical equipoise and potential for intervention, specific or 
attributable to haemodialysis, severity or impact on quality of life, strengthen 
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knowledge and education, and inextricably linked burden and risk.  Patients and health 
professionals believe that cardiovascular outcomes are of critical importance but 
consistently identify sudden cardiac death, myocardial infarction, heart failure and 
stroke as the most important outcomes to be measured in all haemodialysis trials.  
 
Report of the international consensus workshop to establish core cardiovascular 
outcomes (Chapter 4) 
Following the international survey and discussion with the SONG-HD Cardiovascular 
disease Expert Working Group two measures which had been consistently ranked as 
most important, were proposed as core outcome measures of CVD in trials in people 
on haemodialysis: myocardial infarction (MI) and sudden cardiac death (SCD).  We 
convened a consensus workshop to discuss the potential use of these as core outcome 
measures.   Seven patients/caregivers and 51 health-professionals from 15 countries 
discussed selection and implementation of the proposed core outcomes. Five main 
themes were identified. Capturing specific relevance to the haemodialysis population, 
acknowledging prevalence, risk, severity, unique symptomology and pathophysiology. 
The dilemmas in using composite outcomes were recognised. Addressing challenges in 
outcome definitions, establishing a common definition, and addressing uncertainty in 
the utility of biomarkers in haemodialysis. Ensuring a meaningful metric for decision-
making to facilitate comparison across trials.  Enabling and incentivising 
implementation by ensuring cardiologists are involved in development and integration 
of the outcome measure into registries, trial-design and reporting guidelines. Based on 
these themes, participants supported the use of MI and SCD as core outcome 
measures of CVD to be reported in all haemodialysis trials.  
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Incidence of ischaemic heart disease in men and women with ESKD (Chapter 5) 
Ischaemic heart disease (IHD) is the most prevalent of the cardiovascular diseases in 
the ESKD population and myocardial infarction was specifically identified as a critically 
important outcome for research in people on haemodialysis.  The incidence of IHD has 
fallen consistently in the general population; attributed to effective primary prevention 
strategies.  Differences in incidence in the general population have been demonstrated 
by sex.  Whether this fall in incidence and sex differences are mirrored in people with 
ESKD is unclear.  I aimed to establish the relative risk of IHD events in the ESKD 
population.   Using data linkage I performed a cohort study from 2000-2010 in people 
with ESKD in New South Wales.  I calculated incidence rates, incidence rate ratios (IRR), 
and time-trends using indirect standardisation by IHD event.  A total of 10,766 
participants, contributed 44,149 years of observation time. Incidence rates were 
substantially higher than the general population for all IHD events (any IHD event: IRR 
1.8, 95% confidence interval (CI) 1.7-1.9 for men, IRR 3.4, 95%CI 3.1-3.6 for women).  
Excess risk was higher in younger people (age 30-49 IRR 4.8, 95%CI 4.2-5.4), and in 
women with a three-fold increase risk overall and nearly a ten-fold increase in risk in 
young women (female age 30-49 years: IRR 9.8 95%CI 7.7-12.3), results were similar 
for angina and acute myocardial infarction. IHD rates showed some decline for men 
over time, (ratio of IRR 0.93, 95%CI 0.90-0.95) but were stable for women (ratio of IRR 
0.97, 95%CI 0.94-1.01).  People with ESKD have substantially higher rates of IHD than 
the general population, especially women, in whom no improvement appears evident 
over the past 10 years.  
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Cardiac mortality in people with ESKD (Chapter 6) 
Having looked at IHD incidence I wanted to perform a similar study to look at 
mortality; I performed a population-based study across two countries to increase 
generalisability and the accuracy of the risk estimates.  Although in general 
cardiovascular disease refers to pathologies involving the vasculature, heart disease 
including cardiac muscle, valvular pathologies and arrhythmias are also affected in 
ESKD and so we expanded this study to include cardiac disease outcomes.  Cardiac 
disease affects over two-thirds of patients with ESKD and is the leading cause of death 
in this population.  Cardiac death rates have fallen in the general population, but 
benefits from improved preventative therapies and treatment of cardiac events may 
not be generalisable to people with ESKD.  I aimed to review absolute and relative 
rates for cardiac death in the ESKD population compared to the general population.  
Again using data linkage we performed a cohort study of incident people with ESKD in 
Australia and New Zealand from 1980-2013.  We calculated mortality rates for cardiac 
disease as defined by ICD-10-AM codes and standardised mortality ratios (SMR) 
compared with the general population using indirect standardisation, adjusting for 
age, sex, calendar year, and country.   We included 60,823 participants observed over 
381,874 person-years, of whom 34,322 died.  A primary cardiac death was recorded in 
6847 participants (20%) and 27,475 (80%) participants died of other causes.  Absolute 
cardiac death rates in the ESKD population were higher for men than women (men: 
2002, 95%CI: 1945-2062; and women: 1502, 95%CI: 1444-1564/100,000 person-years) 
and both decreased over time.  Relative to the general population, men and women 
with ESKD experienced more deaths (SMR in men: 5.6, 95%CI: 5.5-5.8; and women: 
8.3, 95%CI: 8.0-8.6).  Excess deaths were greatest in younger ESKD patients, 
 xi 
 
particularly women; aged 30-49 years women had 60 times (SMR 60.0, 95%CI: 51.8-
69.0) whereas men had 18 times (SMR 17.7, 95%CI: 15.9-19.7) more deaths than 
expected.  However, among people with ESKD, cardiac death rates improved over time 
more markedly than for the general population, especially in women. Cardiac deaths in 
the Australian and New Zealand ESKD population were higher than expected in the 
general population, particularly at younger ages and for women.  Young women with 
ESKD have an excess relative risk of dying from cardiac causes, though there has been 
some improvement over time.  Disaggregation of these data by sex identifies 
differences which need to be addressed in future research. 
 
Cognition in people with end-stage kidney disease treated with haemodialysis 
(Chapter 7) 
Cerebrovascular disease is prevalent in the ESKD population and associated with 
cognitive impairment which significantly affects quality of life and mortality.   Cognitive 
impairment is under recognised in people with ESKD treated with haemodialysis and 
the severity and the specific patterns of cognitive deficits are poorly understood.  I 
performed a systematic review and meta-analysis of randomised control trials and 
observational studies which used validated neuropsychological tests of cognition in 
adults on haemodialysis compared with the general population, people on peritoneal 
dialysis or people with chronic and ESKD.  Cognitive test scores were aggregated by 
cognitive domain: orientation and attention, perception, memory, language, 
construction and motor performance, concept formation and reasoning, and executive 
functions.  We found 42 studies including 3522 participants.  Studies were mainly of 
high or uncertain risk of bias with high heterogeneity.   We found that people treated 
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with haemodialysis had more impaired cognition than the general population, 
particularly in attention (standardised mean difference (SMD) -0.93, 95% confidence 
intervals (CI) -1.18, -0.68). Haemodialysis patients performed better than non-dialysed 
ESKD in attention (SMD 0.70, CI 0.45, 0.96) and memory (SMD 0.36 CI 0.08, 0.63) but 
had poorer memory than the general population (SMD -0.41 CI -0.91, 0.09) and people 
with CKD (SMD -0.40, CI -0.60, -0.21). There was insufficient data to show other 
differences between people on HD and people on PD or with CKD.  People treated with 
haemodialysis have impaired cognitive function compared to the general population, 
particularly in the domains of orientation, attention and executive function. Cognitive 
deficits in specific domains should be further explored in this population and be 
considered when approaching education and chronic disease management.   
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1.1. Introduction 
The aim of this body of work is to expand our understanding of the interaction 
between cardiovascular disease (CVD) and end stage kidney disease (ESKD).  The 
burden of ESKD is ever increasing and there is a need to prioritise research based on 
the greatest needs of the population, the absolute and relative size of the problem and 
its impact on the individual patient.   
 
The first part of this thesis is concerned with the need to achieve consensus on an 
appropriate measure of CVD for use in trials in people on haemodialysis.  My first 
hypothesis was that the current measures of CVD used in trials were not fit for 
purpose, supporting the need to develop core measures to reduce research waste and 
make outcome measures more relevant to patients and clinicians for use in shared 
decision making (Chapters 2-4).  The second part of this thesis explores the risks and 
patterns of prioritised CVD outcomes. My hypothesis was that the epidemiological 
improvements and sex differences seen in cardiovascular disease outcomes in the 
general population are not mirrored in the ESKD population (Chapters 5 and 6).  Having 
explored patterns of risk I also wanted to examine cerebrovascular aspects of 
cardiovascular disease.  My final hypothesis was that cerebrovascular disease and 
specifically cognitive impairment seen in ESKD patients did not share the same pattern 
of deficits as that seen in the general population. Identifying patterns in cardiovascular 
incidence rates, mortality and pattern differences with the general population allows 
us to more accurately prioritise future directions of research. 
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The specific objectives are:  
1. To describe the current use of cardiovascular outcomes in contemporary trials 
of people on haemodialysis (Chapter 2)  
2. To report the results of an international survey conducted to elicit stakeholder 
opinions on the relative importance of individual cardiovascular outcomes to 
people on haemodialysis (Chapter 3)   
3. To summarise the perspectives of patients on haemodialysis, caregivers and 
health professionals regarding the proposed core outcome measures for 
cardiovascular disease  (Chapter 4)  
4. To examine and describe the incidence rates of cardiac events in the end stage 
kidney disease population and compare them to the cardiac event rates in the 
general population (Chapter 5)  
5. To examine and describe the cardiac mortality rates in the end stage kidney 
disease population and compare them to the cardiac mortality rates in the 
general population (Chapter 6)  
6. To ascertain the impact of cerebrovascular disease in people on haemodialysis 
by describing the patterns of cognitive impairment  (Chapter 7)  
 
This chapter outlines the rationale for the importance of research into ESKD and the 
role that cardiovascular disease has to play.  It summarises the weaknesses in current 
research focussing specifically on cardiovascular outcomes in trials in people with ESKD 
and the gaps in evidence for differences between these outcomes in the ESKD 
population and the general population.   
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1.2. End Stage Kidney Disease 
Worldwide about 13% of the population are affected by chronic kidney disease (CKD)1.  
The incidence of CKD is increasing, in the main due to the increase in cardio-metabolic 
syndrome; driven by over-nutrition and inadequate physical activity, increasing weight 
and obesity.  The risk of CKD progressing to ESKD is relatively small at between 3 and 
8%2 however, worldwide this equates to an estimated 5–10 million deaths annually 
from kidney disease 3.  For those persons who progress to ESKD treatment options are 
dialysis (haemodialysis and peritoneal dialysis), kidney transplantation or supportive 
care.  ESKD leads to high morbidity and mortality and the numbers of people being 
treated for ESKD are projected to increase by about 7% per year4,5. The provision of 
renal replacement therapies (RRT) is expensive and has a substantial economic impact 
both to the individual patient and to society.   
 
1.3. Cardiovascular disease 
CVD is an umbrella term which incorporates diseases of the heart and blood vessels 
including the coronary, cerebral and peripheral vessels.  Globally CVD is the leading 
cause of death. The World Health Organisation project that by 2030 almost 23.6 
million people will die from CVD, and the major contributors are coronary heart 
disease (CHD) and cerebrovascular disease 6.  In the general population the prevalence 
of CVD is higher amongst men than women and increases with age.  The Australian 
burden of disease study which measured the impact of living with illness and injury 
and dying prematurely, found that CHD was the leading individual disease and stroke 
ranked 9th7.  As a result of heath expenditures and lost productivity from increased 
morbidity and mortality, CVD is a significant economic burden to individuals and 
society8.  Most importantly CVD affects physical functioning as well as resulting in 
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neuropsychological sequelae such as depression and cognitive impairment all of which 
can contribute to reduced survival and quality of life. 
 
1.4. ESKD and its relationship to cardiovascular disease 
The Global Burden of Disease 2015 study estimated that 1.2 million deaths, 19 million 
disability-adjusted life-years (DALYs) and 18 million years of life lost from CVD were 
directly attributable to reduced glomerular filtration rates9,10.  CVD is a risk factor for 
both progression of CKD to ESKD as well as an independent risk factor for morbidity 
and mortality in ESKD patients11.  CVD is present in over 50% of people on 
haemodialysis and is the leading cause of death in patients with ESKD12-14.  The high 
risk of CVD in ESKD is partially explained by the high prevalence of traditional risk 
factors for CVD in this population such as diabetes and hypertension15.  Additional 
cardiovascular risk factors are also at play in ESKD including albuminuria, uraemic 
toxins, fluid and electrolyte imbalance, and renal replacement itself16.  These risk 
factors collectively contribute to oxidative stress, inflammation, immune dysfunction 
and disorders of bone and mineral metabolism leading to increased vascular 
calcification and microvascular dysfunction 17-20.    
 
Health related quality of life of patients is significantly lower if patients have CVD in 
addition to ESKD21.  CVD is significantly associated with limitations in mobility and 
physical activity as well as depression, all of which are highly prevalent in people with 
co-existing ESKD and CVD22,23.  There have been links to suggest that psychological 
factors, such as depression and stress are independent risk factors for developing 
CVD23.  This is of particular importance as depression has been identified as the most 
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prevalent psychological illness in the ESKD population24.  People with multiple chronic 
comorbid conditions such as ESKD and CVD are at far higher risk of limitation in their 
daily activities, poorer self-rated health and poorer quality of life. 
 
Given the impact that cardiovascular disease has on the morbidity, mortality and 
quality of life of people with ESKD the inclusion of cardiovascular disease outcomes 
into all research in people with ESKD may help to deliver interventions which make a 
difference to patients’ lives.  
 
1.5. Cardiovascular outcomes in ESKD research 
Cardiovascular disease outcomes 
People with ESKD are frequently excluded from large scale cardiovascular trials25.  Even 
when people with ESKD are included in trials a recent systematic review reported that 
cardiovascular outcomes are infrequently reported, found in only 12% of trials in 
people on haemodialysis 26.  Exclusion of people with ESKD from trials, infrequent 
reporting of CVD outcomes in trials and difficulties comparing CVD outcomes across 
trials has led to significant research wastage and inadequate improvements in 
cardiovascular morbidity and mortality in this high risk population.  Identifying the 
problems with the current utilisation of cardiovascular outcomes in trials of people on 
haemodialysis and attempting to improve the standardisation of that reporting has the 
potential to improve cardiovascular morbidity and mortality for people with ESKD. 
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Core outcome sets and the SONG-HD Initiative 
A core outcome set is an agreed, standardised set of outcomes that should be 
measured and reported, as a minimum, in all clinical trials in specific areas of health or 
health care27. The core outcomes should be based on the shared priorities of patients, 
caregivers, clinicians, researchers, policy makers, and relevant stakeholders.  The aim 
of developing a core outcome set is to ensure evidence from trials is relevant and 
meaningful for patients and healthcare providers in supporting treatment decisions. 
The Standardised Outcomes in Nephrology (SONG) initiative was founded to establish 
a set of core outcomes and their outcome measures for use in trials and research 
across the spectrum of kidney disease.  Using validated methodology a core outcome 
set for haemodialysis was developed: Cardiovascular disease, fatigue, vascular access 
and mortality (Figure 1.1) 26,28,29.  Chapters 2-4 of this thesis are embedded within the 
SONG-HD initiative; to develop core outcome measures for cardiovascular disease. 
FIGURE 1.1 SONG-HD Core Outcome Set 
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1.1 Risks and patterns of CVD outcomes in end stage kidney disease. 
Cardiac events 
The most prevalent cardiac events in this population continue to be driven by coronary 
artery disease; The 2017 United States Renal Data System (USRDS) report stated that 
stable coronary artery disease was the most prevalent disease in ESKD30. The 
Haemodialysis (HEMO) study reported that 40% of dialysis patients had pre-existing 
CVD and that coronary artery disease was the leading cardiovascular cause of hospital 
admissions31.  More recently the EVOLVE study also showed that myocardial infarction 
and heart failure were the most prevalent cardiac events in people on haemodialysis32.   
Cardiovascular morbidity and mortality rates in the general population have improved 
over time and this is largely due to the improvements in treatments and primary and 
secondary prevention33.  Changes in the cardiac event and mortality rates in the ESKD 
population have not been so well described.  I wanted to examine the differences in 
cardiac event rates and cardiac mortality rates between the ESKD population and the 
general population and review the changes over time.  The Australia and New Zealand 
Dialysis and Transplant Registry (ANZDATA) is a clinical quality registry that collects 
data relating to treatment and outcomes from all renal units in Australia and New 
Zealand.   This registry allows comprehensive reporting on incidence, prevalence and 
outcomes of dialysis and transplant treatment for patients with ESKD across Australia 
and New Zealand.   I wanted to use linked data to be able to provide unbiased 
comparisons between this ESKD group and the general population.. 
Impact of cerebrovascular changes 
Cerebrovascular disease is a leading cause of CVD in people with ESKD with the risk of 
stroke thirty times higher than in the general population34.  Cognitive impairment is 
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also highly prevalent in the ESKD population with some studies describing prevalence 
rates of up to 70%35.  The pathogenesis of cognitive impairment is likely to be 
multifactorial but may be similar to that responsible for cognitive decline associated 
with other CVD; atherosclerosis, clinical and silent stroke, oxidative stress, and white 
matter lesions36. There are however, additional uraemia related risk factors potentially 
contributing to the high prevalence of microvascular changes in ESKD which have been 
associated with cognitive impairment37,38.  Furthermore, haemodialysis treatment has 
been shown to affect cerebral blood flow correlating to intradialytic variations in 
cognitive function39.  
 
Cognitive impairment can have a significant impact on quality of life and has been 
shown to affect mortality40,41.    Cognitive impairment in people with ESKD is poorly 
understood, particularly which cognitive domains are affected and how the pattern of 
deficits compares to the general population.  The majority of studies have only 
recruited small numbers and comparator groups have varied.  I wanted to pool 
available data to identify the cognitive domains most affected in people on 
haemodialysis and compare this to the general population and other renal 
replacement therapies. 
 
These following chapters attempt to distil the evidence, improve standardisation of 
CVD outcomes and describe the differences in cardiovascular disease between the 
ESKD population and the general population.  
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2.1  Abstract 
Patients on long-term haemodialysis are at very high risk for cardiovascular disease, 
but are usually excluded from clinical trials conducted in the general population or in 
at-risk populations. There are no universally agreed cardiovascular outcomes for trials 
conducted specifically in the haemodialysis population. In this review we highlight that 
trials reporting cardiovascular outcomes in haemodialysis patients are usually of short 
duration (median = 3 to 6 months) and are small (59% of trials have less than 100 
participants).  Overall, the cardiovascular outcomes are very heterogeneous and may 
not reflect outcomes that are meaningful to patients and clinicians in supporting 
decision making, as they are often surrogates of uncertain clinical importance. 
Composite outcomes used in different trials rarely share the same components. In a 
field where a single trial is often insufficiently powered to fully assess clinical and 
economic impact of interventions, differences in outcome reporting across trials 
makes the task of meta-analysis and interpretation of all the available evidence 
challenging. Core outcomes sets are now being established across many specialties in 
healthcare to prevent these problems. Through the global Standardised Outcomes in 
Nephrology - Haemodialysis (SONG-HD) initiative, cardiovascular disease was identified 
as a critically important core domain to be reported in all trials in haemodialysis. 
Informed by the current state of reporting of cardiovascular outcomes, a core outcome 
measure for cardiovascular disease is currently being established with involvement of 
patients, caregivers and health professionals. Consistent reporting of cardiovascular 
outcomes that are critically important to haemodialysis patients and clinicians will 
strengthen the evidence base to inform care in this very high-risk population.  
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2.2 Introduction 
“When I use a word," Humpty Dumpty said, in rather a scornful tone, "it means just 
what I choose it to mean- neither more nor less." "The question is," said Alice, 
"whether you can make words mean so many different things." In writing Through the 
Looking Glass 1, Lewis Carrol could have been referring to cardiovascular outcomes 
reported in clinical trials, particularly among patients on haemodialysis. 
 
2.3 Cardiovascular disease and haemodialysis 
Worldwide, more than two million people have end stage kidney disease (ESKD), with 
this number increasing annually by 5-7% 2. Patients with ESKD who are treated with 
dialysis require a disproportionately high use of health-care resources. The prevalence 
of cardiovascular disease (CVD) in people on haemodialysis exceeds 60% 3,4 and 
accounts for over 50% of deaths 4-6. CVD mortality remains up to 30 times higher in 
people on dialysis than in the general population 6.  
 
2.4 The importance of an outcome 
Clinical trials of interventions designed to reduce CVD in people with ESKD have 
evaluated the use of medications 7-10, and the intensity and type of haemodialysis 11-13, 
but the results have generally not identified clear evidence of benefit. Such trials may 
have been less informative than possible because they were too small to identify 
modest but realistic treatment effects, and inconsistencies in how cardiovascular 
outcomes were measured and reported made it difficult to compare the effectiveness 
of interventions across different trials or to combine trial results in meta-analyses 14. 
Reporting bias, both in terms of selective outcome reporting and publication bias, also 
has the potential to cause misinterpretation of evidence 15.  The value of trials to 
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inform decision-making among patients, clinicians, and policy makers may also be 
reduced if the outcomes are selected on the basis of feasibility rather than importance 
16.  
 
The importance of choosing the right outcomes for clinical trials to inform decision 
making is widely accepted, but appropriate measurement of cardiovascular outcomes 
in trials can be challenging. In particular, the major cardiovascular outcomes occur only 
in a relatively small fraction of participants meaning, unless trials are very large, follow-
up periods may need to be long in order to capture a sufficient number of specific 
events. This has led to an increasing use of composite outcomes to increase the 
number of events captured and to reduce sample size requirements 17,18. When using 
composite endpoints, it is difficult to estimate the true effect of an intervention on 
different components of the composite, particularly those that occur less frequently.  
Composites often combine outcomes with very different levels of importance to 
patients, making interpretation of the overall importance of the trial findings difficult 
18,19. Similarly, a compounding problem is that inclusion of surrogates  diverts attention 
from outcomes of more importance to patients and clinicians 20. Outcomes need to be 
relevant to all stakeholders, in particular the patients within the specific disease 
group21.  
 
The capacity to compare outcomes across trials and produce summary effect estimates 
through meta-analysis would help to improve confidence in the effects of 
interventions in the haemodialysis population, but would require that the outcomes 
are reported consistently.   
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2.5 The need for core outcome sets 
A core outcome set is an agreed standardised set of outcomes that should be 
measured and reported, as a minimum, in all clinical trials in the relevant areas of 
health or healthcare 22. 
 
Recently, there has been a proliferation of discipline-specific and global initiatives to 
develop core outcome sets 23,24. The Outcome Measures in Rheumatology (OMERACT) 
initiative was formed in 1992 and set the foundation for the development of core 
outcomes, specifically in rheumatology trials. With the involvement of patients, health 
care providers, and policy makers, OMERACT has improved the relevance of outcomes 
reported in rheumatology trials. More recently, the Core Outcome Measures in 
Effectiveness Trials (COMET) initiative was established to facilitate the development 
and collation of core outcome sets across all diseases internationally (23).  
 
Among cardiovascular trialists, there have been concerted efforts to standardize 
cardiovascular outcome reporting 25-27. Early attempts include the introduction of the 
term MACE, defined as 'major adverse cardiac events,' in the mid-1990s with its use 
theoretically restricted to in-hospital complications related to percutaneous coronary 
interventions 28. However, the components of a “MACE” vary, even between trials of 
similar interventions. For example, a systematic review assessing the components of 
MACE used in studies comparing bare metal versus drug-eluting stents, found large-
scale heterogeneity in the outcomes used29.  The use of MACE has become 
widespread, but is often used outside its original context with large number of varied 
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outcome measures used to make up the composite endpoint 29.  More recently, a 
number of core outcome sets have been developed for cardiovascular diseases in 
specific populations including a set for the effectiveness of cardiac surgery 30, and a set 
for pregnant women with cardiovascular disease 31.    
 
2.6 Current state of reporting of CVD outcomes in haemodialysis trials 
A systematic search was conducted in MEDLINE, Embase, the Cochrane Kidney and 
Transplant Specialized Register, and ClinicalTrials.gov for randomised controlled trials 
conducted in adults on haemodialysis (both published or in progress, from 2011 to 
2017), which reported at least one cardiovascular outcome. We extracted a number of 
trial characteristics as well as all cardiovascular outcome measures, including all levels 
of specification(if reported), and the specific metric (e.g. time to event, change from 
baseline), method of aggregation (e.g. mean, median, proportion) and time point of 
measurement 32.   
 
We classified the outcomes into 236 measures (e.g. troponin) and then again into 
twenty-six outcome groups (e.g. cardiac biomarker).  A schema of the categorization is 
provided in Appendix 1 Figure 1 with an example in Appendix 1 Table 2. Outcomes 
were further classified as surrogate, clinical or patient-reported. A surrogate outcome 
was defined as a biochemical, imaging, or other marker used as a substitute for a 
clinical outcome 33.  A clinical outcome was defined as a medical event or comorbidity 
(e.g. mortality, myocardial infarction, hospitalization) diagnosed by the clinician.   
Patient-reported outcomes were those reported directly by patients regarding how 
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they function or feel in relation to a health condition and its therapy, without 
interpretation by a healthcare professional or anyone else 34.   
 
Trial characteristics 
We identified and included 174 trials involving 148,730 participants (Figure 2.1). Trial 
characteristics are presented in Table 1. Fifty-six (32%) trials were unpublished. The 
published trials were conducted across 28 countries, most frequently in Japan (8%) and 
the USA (8%), and 12 (7%) trials were multinational. The median (interquartile range 
[IQR]) trial duration was 15.0 months (IQR 5.5 to 42.0 months) and the median sample 
size was 83 participants (IQR 32 to 200 participants). It is of note that relative to many 
cardiovascular trials in the general population, both the trial duration and the sample 
size is small.  The most common type of intervention was pharmacological (103 [60%] 
trials). In 48 (27%) trials, the intervention was a dialysate, dialysis membrane or 
modality of haemodialysis (such as haemodiafiltration or haemodialysis). 
 
Outcomes and outcome measures 
The 1743 definitions (including different time points of measurement) were 
categorised into 236 measures (e.g. troponin), with a median of 3.5 outcome measures 
reported per trial (range 1 to 23). Across all trials, measures were assessed at 67 
different time points with a range of one to six time points per trial. The number of 
measures was not associated with the sample size (Appendix 1 Table 3). These 
measures were further grouped into 26 outcomes (e.g. cardiac biomarkers), with a 
median of two outcomes reported per trial (range 1 to 16). Of the 26 outcomes, 15 
(58%) were clinical, 10 (38%) were surrogates and one (4%), was a patient-reported 
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outcome – pain. (Figure 2.2) The top three most frequently reported outcomes were: 
serum biomarker (biomarkers excluding lipids and traditional cardiac biomarkers) (52 
[30%] trials), cardiovascular composite (52 [30%] trials), and serum lipid levels (41 
[23%] trials).   
 
The number of measures for each outcome ranged from 1 to 61 (Figure 2.3). The 
serum biomarker outcome included 61 different biomarker measures; C-reactive 
protein was the most frequently reported biomarker (34 [20%] trials) followed by 
homocysteine (8[5%] trials). The outcome cardiovascular composite included 11 
composite measures, the three most frequent being a “cardiovascular composite” 
measure (e.g. “the cumulate rate of non-fatal MI or acute coronary syndrome, 
hospitalization for heart failure, nonfatal stroke or CV death” (27 [16%] trials), a 
“cardiovascular event” (e.g. “rate of cardiovascular events” (24 [14%] trials) and 
“cardiovascular event non-fatal” (4 [2%] trials) (Figure 2.3). The outcome serum lipid 
levels had ten different measures, the three most frequently reported being “HDL” (26 
trials [15%], “triglycerides” (26 [15%] trials and “total cholesterol” (21 [12%] trials.  
Across the clinical outcomes, there were 13 different metrics used to report the 
original definitions and these included:  number of events, rate of event, event free 
survival and time to event.  The methods of aggregation for the clinical outcomes 
included mean, median, proportion and proportional change. 
 
Cardiovascular composite outcome 
Each composite measure was deconstructed into its components and the number of 
trials using each component was analysed as shown in Figure 2.4. Fifty-one trials (29%) 
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used a cardiovascular composite measure and each trial used a range of one to six 
different composite combinations. Within these 51 trials there were 50 unique 
composite combinations (Figure 2.4).   The proportion of trials reporting each measure 
within the cardiovascular composite outcome is shown in Appendix 1 Figure 2. 
 
Mortality outcomes 
A cardiovascular mortality outcome was reported in 25 (14%) trials.  Included in the 
mortality outcome were eight individual events of which “sudden cardiac death” was 
the most frequently reported (seven [4%] trials) (Appendix 1 Figure 3).  A composite 
mortality measure was assessed in 14 (8%) trials and 12 composite combinations were 
used (Figure 2.5).  Within the mortality outcome, the most frequently reported 
composite outcome measure was Cardiovascular death, reported as a unique term in 
16 (9%) trials and also used in five (42%) mortality composite combinations (Figure 
2.5).  
 
2.7 Time for more confidence in outcomes 
In contemporary clinical trials conducted in patients on haemodialysis, a very large 
number of different cardiovascular outcomes have been reported. Over a third of 
these outcomes were classified as surrogates rather than outcomes that would be 
expected to be directly important to patients and clinicians (such as sudden cardiac 
death, myocardial infarction), and only one was patient-reported (pain). The use of 
surrogate outcomes is probably a function of the small sample size of most of the trials 
identified.  Use of composite outcomes was common being used in a third of the trials, 
but each trial used different components to make up their composites and they were 
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often ill-defined, making comparisons across studies problematic. This echoes the 
findings in other populations regarding the complexity and discord within composite 
outcomes 18,29.  A review of composite outcomes within cardiovascular trials found 
that the components of composite endpoints varied widely in terms of their 
importance to patients and in the magnitude of their effect of the intervention. This 
can give rise to misleading interpretations regarding the impact of treatment 18.  
The variety of measures used to assess each outcome was substantial, particularly 
among the surrogate outcomes; with over 60 different serum biomarkers measured 
and over 30 different ways to measure vascular function and anatomy.  Heterogeneity 
was evident at multiple levels including definition of the measurement, the metric, the 
method of aggregation and the time point of measurement of the outcome measure.  
This heterogeneity is not unique to the haemodialysis population. In a review of 
outcomes in cardiac arrest trials, over 160 individual outcomes were reported, 
including 39 different measures of survival 35.  
 
This review highlights the urgent need to develop a core outcome set in haemodialysis 
trials. Recently, the Standardized Outcomes in Nephrology (SONG) initiative was 
established, which has used validated consensus methodology to bring together 
patients and health care professionals to identify critically important outcomes in 
haemodialysis 36-38. Cardiovascular disease was identified as a core outcome domain 
(along with vascular access, fatigue and mortality).   The next phase of the SONG 
initiative aims to establish these core measures with consensus on their definition. 
Moving forward, this effort will facilitate improvement in the quality, transparency and 
value of cardiovascular trials in people on haemodialysis, and most importantly, has 
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the potential to improve interpretation of clinical trials data in the hope of reducing 
mortality and morbidity for people on haemodialysis. 
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2.9 Figures and tables 
FIGURE 2.1 SEARCH RESULTS 
Comprehensive literature search of MEDLINE, Embase, the Cochrane Kidney and 
Transplant Specialized Register, and ClinicalTrials.gov from 2011 to 2017 resulted in 
174 randomised trials in patients on haemodialysis reporting at least one 
cardiovascular outcome. 
HD = Haemodialysis, CVD = cardiovascular disease 
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FIGURE 2.2  PROPORTION OF TRIALS REPORTING EACH OUTCOME (174 TRIALS, 26 
OUTCOMES) 
Chart to show the 26 outcome groups determined from the 174 trials and the 
proportion of trials which reported them. The most frequently reported outcomes 
were the surrogate outcome of serum biomarker and a cardiovascular composite 
outcome. Only one outcome was patient reported. 
ACS - Acute coronary syndrome, ECG- Electrocardiogram 
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FIGURE 2.3 NUMBER OF UNIQUE MEASURES WITHIN EACH OUTCOME GROUP 
Bar chart to show how the number of different measures that contributed to each 
outcome excluding time points. There were 61 different biomarkers measured in the 
outcome group Other serum biomarkers, and 32 different ways of measuring Vascular 
function and anatomy.  
ACS – Acute coronary syndrome, CV – cardiovascular, ECG – electrocardiogram, MI – 
Myocardial infarction, PVD – Peripheral vascular disease 
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FIGURE 2.4 CARDIOVASCULAR COMPOSITE MATRIX.  
Individual components of the 51 composite outcomes after deconstruction.  The far right column tallies the number of trials that utilised each composite and the bottom 
row tallies the number of times each component was incorporated into a composite.  
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US= unspecified, Dx=disease, Hosp=hospitalisation, MACE=Major adverse cardiovascular event,  NF= non fatal,  SAE= Serious adverse event, 
Morb=morbidity, DVT=deep vein thrombosis, PE=pulmonary embolism, VA=vascular access, throm=thrombosis, Embol=embolism, Ang=angina, ACS=acute 
coronary syndrome, CHD=coronary heart disease, cor=coronary, MI=myocardial infarction, TIA=transient ischaemic attack, CVA=cerebrovascular, 
haem=hemorrhagic, CA=cardiac arrest, cereb=cerebrovascular, VF=cardiac arrhythmia, AS= Atherosclerotic, morb= morbidity 
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FIGURE 2.5 MORTALITY COMPOSITE MATRIX 
Matrix to show the individual components of the 12 composites after deconstruction.   
The far right column tallies the number of trials that utilised each composite and the 
bottom row tallies the number of times each component was incorporated into a 
composite.  The composite Cardiovascular death was used in 16 trials but was not 
further defined. 
 
 
CV = cardiovascular, CHD=coronary heart disease, haem=hemorrhagic , MI=myocardial 
infarction, SCD=sudden cardiac death, US=unspecified 
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TABLE 2.1 CHARACTERISTICS OF INCLUDED TRIALS (TOTAL=174) 
Characteristics  Number of trials % 
Participants (n) 0-49 64 38 
 50-99 35 21 
 100-499 49 29 
 500-999 10 6 
 1000-4999 9 5 
 =>5000 2 1 
 Not stated 5 3 
Year of publication 2011-2012 50 29 
 2013-2014 52 30 
 2015-2016 16 9 
 Not published 56 32 
Region/Country Not stated 64 37 
 Europe 43 25 
 Asia 23 13 
 USA 13 7 
 International 12 7 
 Middle East 11 6 
 South/Central America 4 2 
 Australasia 4 2 
Duration of trial  (months) 1 to 3 8 7 
 >3 to 6 24 20 
 >6 to 12 11 9 
 >12 to 24 28 23 
 >24 to 48 23 19 
 >48 27 22 
 Not stated 53 30 
Intervention type Pharmacological/Supplement 104 60 
 Dialysate 22 13 
 Mode of haemodialysis 26 15 
 Lifestyle 6 3 
 Other 5 3 
 Dialysis Machine 9 5 
 Coronary intervention 3 2 
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CHAPTER 3  
IDENTIFYING CRITICALLY IMPORTANT CARDIOVASCULAR 
OUTCOMES FOR TRIALS IN HAEMODIALYSIS: AN 
INTERNATIONAL SURVEY WITH PATIENTS, CAREGIVERS 
AND HEALTH PROFESSIONALS 
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3.1 Abstract 
Background:  Cardiovascular disease (CVD) is a major contributor to morbidity and mortality 
in people on haemodialysis. Cardiovascular outcomes are reported infrequently and 
inconsistently across trials in haemodialysis.  This study aimed to identify the priorities of 
patients/caregivers and health professionals for CVD outcomes to be incorporated into a 
core outcome set reported in all haemodialysis trials. 
Methods: In an international online survey, participants rated the absolute importance of 
ten cardiovascular outcomes (derived from a systematic review) on a 9-point Likert Scale, 7-
9 being critically important.  Relative importance was determined using a best-worst scale. 
Likert means, medians and proportions and best-worst preference scores were calculated 
for each outcome. Comments were thematically analysed. 
Results: Participants included 127 (19%) patients/caregivers and 549 (81%) health 
professionals from 53 countries; of whom 530 (78%) completed the survey in English and 
146 (22%) in Chinese.  All but one CV outcome (valve replacement) was rated as critically 
important (Likert 7-9) by all participants. Patients/caregivers ranked sudden cardiac death, 
heart attack, stroke and heart failure as the most important outcomes with mean 
preference scores and 95% CI of 6.2 (4.8-7.5), 5.9 (4.6-7.2), 5.3 (4.0-6.6) and 4.9 (3.6-6.3).  
The same four outcomes were ranked most highly by health professionals.  We identified 
five themes for the prioritisation of outcomes: clinical equipoise and potential for 
intervention, specific or attributable to haemodialysis, severity or impact on quality of life, 
strengthen knowledge and education, and inextricably linked burden and risk. 
Conclusions: Patients and health professionals believe that all cardiovascular outcomes are 
of critical importance but consistently identify sudden cardiac death, myocardial infarction, 
heart failure and stroke as the most important outcomes to be measured in all 
haemodialysis trials.  
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3.2 Introduction 
People on haemodialysis have a risk of cardiovascular death 20 times greater than that 
found in the general population 1.  Cardiovascular death accounts for nearly 50% of 
mortality in the haemodialysis population 1,2.  There is a high prevalence of cardiovascular 
risk factors in people on haemodialysis including hypertension and diabetes 3,4, as well as 
uremic toxins, fluid and electrolyte imbalance, metabolic bone disease and persistent 
inflammation 5,6. Cardiovascular disease is a substantial contributor to morbidity and 
impaired quality of life in patients on haemodialysis.  
 
Patients with kidney failure are often excluded from cardiovascular trials7.  Unfortunately, 
the majority of interventions which have been studied in this population have not been 
found to improve cardiovascular mortality 8,9.   Cardiovascular outcomes are reported in 
only 12% of all trials in haemodialysis and have used over 47 different measures assessed at 
many different time points10.  The relevance and importance of these outcomes to patients 
and clinicians remains unknown11.   These limitations make decisions regarding the 
management of CVD in people on haemodialysis challenging and highlight the need for 
consistent reporting of outcomes across trials. 
 
The Standardized Outcomes in Nephrology - Haemodialysis (SONG-HD) initiative has 
established cardiovascular disease as a core outcome domain for clinical trials in 
haemodialysis (as well as mortality, vascular access and fatigue)10,12,13.  Standardised core 
outcome measures of cardiovascular disease need to be developed based on the shared 
priorities of patients, caregivers, clinicians, researchers, policy makers, and relevant 
stakeholders.  The aim of this survey is to assess the absolute importance of cardiovascular 
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outcomes and their importance relative to each other outcome to determine the most 
important outcomes to be used as core measures of cardiovascular disease in trials.  
 
3.3 Materials and Methods 
Study Design 
We conducted an international online survey to assess the absolute and relative importance 
of cardiovascular outcomes for use in all haemodialysis trials. The survey was administered 
online and available in English and Chinese languages.   
 
Outcome inclusion 
We identified cardiovascular outcomes based on a systematic review of cardiovascular 
outcomes reported in contemporary trials 11.  Composite outcomes were excluded from the 
survey but were deconstructed into respective components.  Surrogate cardiovascular 
outcomes (e.g. left ventricular mass) and biomarkers (e.g. troponin) were not included as 
they are unlikely to be meaningful to patients, may not be validated in this population and 
may not automatically translate into health benefits14.  The selection of outcomes was 
further informed by comments on CVD in haemodialysis from patients and caregivers in a 
previously published international Delphi survey13 and discussion among the Expert Working 
Group.  Ten outcomes were included in the survey and were accompanied by a plain 
language definition (Box 3.1).  
 
Survey  
The survey was translated into Chinese (Mandarin) by a professional translator and cross 
checked by a bilingual health professional to ensure the true meaning was interpreted.  The 
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survey was piloted on 6 participants in each language and included patients, caregivers and 
healthcare professionals.   
 
The absolute importance was assessed using a Likert scale, where each outcome was scored 
from 1-9.  A score of 7-9 indicated that the outcome was of “critical importance”, 4-6 
indicated “important but not critical” and 1-3 indicated “limited importance”.  Participants 
were given an option to choose “uncertain” and could provide additional comments. To 
ascertain relative importance a Best-worse scale (BWS) survey was used.  Each participant 
was presented with five choice sets each consisting of 5 of the 10 outcomes that were 
varied across the choice sets. For each choice set participants were asked to choose which 
was the most and which the least important outcome. The combination of outcomes across 
the choice sets was determined using a balanced incomplete block design15. The BWS scale 
is a preference elicitation method based on the theory underpinning discrete choice 
experiments but involves less cognitive burden and provides better discrimination between 
outcomes than the Likert scale and greater information retrieval16-18. The survey was 
completed using LimeSurvey from October 2016 to December 2018.   
 
Participant recruitment 
Adult patients aged over 18 years, caregivers/family members, nephrologists, cardiologists, 
allied health members, policy makers, researchers, and industry representatives with 
interest or experience in haemodialysis were eligible.  To ensure broad representation 
multiple recruitment strategies were used. Patients and caregivers were invited via the 
SONG Initiative database and patient organizations worldwide using standardised invitation 
fliers; and via opt-in snowball sampling which included the use of social media. Health 
professionals were recruited via professional organizations via standardised email 
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invitations or newsletters to their membership list, investigator networks, and via the SONG 
database. Participants registered their email on the SONG website to receive an email 
invitation with a unique survey link. All participants provided informed consent. The study 
was approved by the ethics board of The University of Sydney (2015-228). 
 
Data Analysis 
For each CV outcome the absolute importance was assessed by calculating the mean, 
median, and the proportion of participants who rated the outcome as critically important 
(scores of 7-9 on the Likert Scale).  Relative importance was determined using a multinomial 
logistic regression model and expressed as a mean relative importance score determined 
from the regression coefficients for each outcome. As the regression coefficients have the 
same underlying scale, preference scores can be adjusted to any convenient scale to aid 
interpretation.   Absolute importance scores were calculated separately for 
patients/caregivers and health professionals while relative importance scores were 
calculated using interaction terms in the regression model. Mean differences in absolute 
(Likert) and relative (BWS) importance scores between stakeholder groups and respective 
95% confidence intervals (CI) were calculated. The software packages Excel (Microsoft 
Corporation, Product version 16.0), Stata/SE version 14.0 (StataCorp. College Station, TX) 
and NLOGIT V6 (Econometric Software Inc.) were used to analyse the data.  
All free text comments from the survey responses were extracted. Comments in Chinese 
were translated by two independent translators and all comments were imported into 
HyperRESEARCH (Version 3.7, Randolph, MA) software. Using thematic analysis, investigator 
EO conducted line-by-line coding of the text to inductively identify themes that reflected the 
reasons for their prioritization.  The thematic analysis was cross checked by a second 
investigator (AT).  
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3.4 Results 
In total, 676 participants completed the survey, 127 (19%) were patients/caregivers (112 
patients and 15 caregivers) and 549 (81%) were healthcare professionals; the majority were 
nephrologists (63%).  The majority of participants completed the survey in English (530 
[78.4%]) with 146 (21.6%) completing the Chinese survey. The characteristics of 
patients/caregivers and health professionals are shown in Tables 3.1 and 3.2 respectively.   
Of the total cohort 315 (46.6%) were male.  Participants were from 53 countries with the 
majority from China (26%), Europe (23%) and Australia/ New Zealand (19%).  The majority 
(78%) of the patient/caregiver participants had experienced a cardiovascular event. 
 
Absolute importance 
All CV outcomes were considered critically important (7-9 on the Likert scale) by 
patients/caregivers and health professionals with mean scores greater than 7 with the 
exception of valve replacement for health professionals that had a mean absolute 
importance score of 6.8 (95% CI 6.7 to 7.0).  Based on mean scores the top three highest 
rated outcomes by all participants were heart attack (8.34, 95% CI 8.24 to 8.43), sudden 
cardiac death (8.34, 95% CI 8.29 to 8.40, and heart failure (8.24, 95% CI 8.15 to 8.33) (Figure 
3.1).  The three outcomes rated highest by patients/caregivers, based on mean scores, were 
heart attack (8.25, 95% CI 8.04 to 8.48), stroke (8.18, 95%CI 7.93 to 8.43) and heart failure 
(8.15, 95%CI 7.95 to 8.35) (Table 3.3). For health professionals, the top three outcomes 
were: sudden cardiac death (8.41, 95% CI 8.29 to 8.52), myocardial infarction (8.35, 95% CI 
8.24 to 8.50) and heart failure (8.26, 95% CI 8.16 to 8.37) (Table 3.3). 
 
Relative importance 
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Patients/caregivers ranked sudden cardiac death, heart attack, stroke and heart failure as 
the most important outcomes with mean preference scores and 95% CI of 6.2 (4.8-7.5), 5.9 
(4.6-7.2), 5.3 (4.0-6.6) and 4.9 (3.6-6.3) respectively (Figure 3.2). The confidence limits for 
the top four outcomes overlapped suggesting little or no difference in relative importance.  
Health professionals ranked the same four outcomes as most important and again with 
similar relative importance  with the exception of sudden cardiac death that was clearly 
ranked as the most important outcome with a mean importance score of 9.0 (8.7-9.3) (Table 
3.3).  The least important outcome to patients/caregivers was Angina with a mean 
preference score of 1 (95%CI -0.32 to 2.32) and for healthcare professionals it was the 
reference outcome valve replacement with a mean preference score of 1.53. 
 
Subgroup analysis  
The mean differences in absolute importance scores between patients/caregivers and 
health professionals for the four highest rated outcomes sudden cardiac death, heart attack, 
stroke and heart failure were similar (P > 0.05). There were too few Chinese 
patients/caregivers to enable us to perform subgroup analysis between the 
patient/caregiver groups by language.  However, differences were evident between English 
and Chinese language health professionals (Figure 3.3). The top four most important 
outcomes for English language participants were sudden cardiac death, heart attack, stroke 
and heart failure, while the top four for Chinese language participants were heart attack, 
heart failure, sudden cardiac death and clots. Differences in absolute mean scores were 
evident for all outcomes (P<0.05) with the exception of sudden cardiac death and peripheral 
vascular disease (PVD) (P>0.05). The relative preferences for English and Chinese language 
participants were generally similar (Figure 3.3), with the exception of stroke and PVD both 
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of which were considered less important (P<0.05) by health professionals who completed 
the survey in Chinese.  
 
Themes 
From the free text comments we identified five themes for the prioritisation of outcomes:  
clinical equipoise and potential for intervention, specific or attributable to haemodialysis, the 
severity or impact on quality of life, strengthen knowledge and education and inextricably 
linked burden and risk.  Selected comments for each theme are provided in Table 3.4. 
 
Clinical equipoise and potential for intervention 
Both professionals and patients believed that outcomes with potential for intervention were 
more important, “I've rated higher conditions where intervention could save a life or 
prevent serious incapacity” (health professional). Health professionals felt that outcomes 
with clinical equipoise should be prioritized for research, “I would have rated arrhythmia 
higher if I could, particularly atrial fibrillation, as this is a significant area of equipoise” 
(health professional).   Patients considered the ability to control the outcome with lifestyle 
intervention – “the heart is a problem but with controlled food there is a better outcome 
that is more affordable” (patient). 
 
Specific or attributable to haemodialysis 
Outcomes specific to patients on haemodialysis were deemed to be particularly important, 
“I chose sudden cardiac death as I believe it is a particular problem in dialysis patients” 
(patient). Patients and health professionals noted that patients on dialysis and also the 
transplant waiting list were particularly vulnerable as a cardiovascular event may prevent 
access to transplantation: “outcomes that affect suitability for transplantation are of critical 
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importance” (health professional). This was also reinforced by patients/caregivers – “we are 
put on hold on the transplant list until the heart issues are fixed” (caregiver). Some 
indicated that cardiovascular outcomes may present differently in people on haemodialysis, 
“traditional cardiac vessel occlusion is not the issue in most cases” (health professional).  
Participants considered that outcomes directly attributable to haemodialysis were of critical 
importance and needed to be recognized, “I believe the heart damage and other side-
effects of dialysis are not only preventable, but severely understated” (patient). They also 
considered the increased risk of CVD associated with medications prescribed for patients on 
dialysis – “for dialysis patients heart disease [because of medication] is something we have 
to deal with” (patient/caregiver).  
 
Severity or impact on quality of life 
Participants believed that outcomes which had a debilitating and broader impact on quality 
of life were important.  One patient stated that their experience of multiple cardiovascular 
events continued to “greatly impact on my life with good kidney function”.  Some health 
professionals prioritized the outcomes based on the impact they observed or believed it had 
on the patients – “I used my sense as to how much patients tend to be impacted by each 
outcome and how frequently we see each outcome in patients on haemodialysis in 
prioritizing between outcomes.” 
 
Strengthen knowledge and education 
Patients and health professionals prioritized outcomes based on consideration of knowledge 
and education about specific cardiovascular outcomes in haemodialysis – “cardiovascular 
pathology as a long term disease requires both patients and medical team continuous 
education” (HPR).  Patients believed that some CVD outcomes were missed or overlooked, 
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“left ventricular hypertrophy is often forgotten by health professionals and leads to 
complications for patients in dialysis” (patient/caregiver).  Patients wanted to highlight the 
need for education regarding cardiovascular disease so they could gain control and employ 
self-management, “it is important to educate the patients. If the patient knows what is 
going on with their body, they can manage to prevent unnecessary complications” 
(patient/caregiver).   
 
Inextricably linked burden and risk,  
Health professionals often prioritized outcomes that were highly prevalent in the 
haemodialysis population – “my view of importance was influenced in part by frequency” 
(health professionals).  Participants agreed that cardiovascular outcomes were critical, “all 
are important and matter, both independently and as variables within the sphere of each 
other” (health professional) and that “in many cases they [outcomes] can not be arbitrarily 
separated’ (health professional). Patients expressed similar concerns regarding the 
importance of all outcomes “[it is] very difficult to choose what is the most important and in 
need of the most study....It would seem that we need to know more about this cardiac 
problem so that we can find ways to prevent this devastating problem” (patient). 
 
 
3.5 Discussion 
All cardiovascular outcomes were seen as critically important to stakeholders. Prioritisation 
was given to sudden cardiac death, heart attack, heart failure and stroke by 
patients/caregivers and health professionals and these outcomes were consistently the 
most important across survey languages.  Participants prioritized outcomes for many 
practical reasons, selecting outcomes because of their prevalence in haemodialysis or 
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perceived causation by haemodialysis.  Participants also wanted to ensure that outcomes 
which had most impact on quality of life and highest likelihood of improvement from 
interventions were ranked most highly.  
 
Sudden cardiac death and myocardial infarction were highly prioritised outcomes by all 
stakeholders.   Other studies which have focussed on patient preference elicitation, albeit in 
the general population, have prioritized similar outcomes 19.  Interestingly, participants in 
this general population study added that when patients are involved in outcome selection 
and trial design, they are more likely to comply with the intervention 19.  Sudden cardiac 
death was ranked highest by all stakeholders which aligns with the disproportionately high   
rate of sudden cardiac death in the haemodialysis population 20-22.  There are a number of 
risk factors specific to people on haemodialysis which influences the  high prevalence 
namely; large and regular shifts in fluid and electrolytes a high prevalence of left ventricular 
hypertrophy and vascular calcification23.  The patterns of arrhythmias in haemodialysis 
patients differ from those in the general population and it is likely that the pathophysiology 
of sudden cardiac death is also different in haemodialysis22.   It is possible that a number of 
participants had witnessed a sudden cardiac death or other acute CVD event on the dialysis 
unit.  There is no research specific to the dialysis unit to determine what effect these 
experiences might have on patient or healthcare professionals’ attitudes towards this 
outcome.   Nonetheless, it is known that there are a number of psychological sequelae  after 
witnessing an unsuccessful resuscitation attempt24 and this is highly likely to affect 
prioritisation of outcomes.   
 
Heart failure and myocardial infarction (MI) are similarly important to all stakeholders in this 
survey.  Heart failure is an outcome which is clinically difficult to define in the dialysis 
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population as symptoms often overlap with excess fluid.  The cause of heart failure can be 
multifactorial but is often secondary to ischaemic heart disease and survived myocardial 
infarction.  Both heart failure and myocardial infarction have far reaching consequences on 
quality of life and survival 25.  All-cause mortality of dialysis patients with acute myocardial 
infarction (AMI) at 2 years is 58% and this is 20% lower than in people with  ESKD with no 
AMI26.  The incidence and mortality rate of myocardial infarction in the haemodialysis 
population exceeds that of the general population by over 20 times 27.  There is increasing 
evidence that prevention, diagnosis and treatment of MI in the haemodialysis population is 
inferior to that found in the general population resulting in poorer short term and long term 
prognosis28-30. Furthermore, haemodialysis patients are often excluded in large scale trials of 
primary and secondary preventative therapies for ischaemic heart disease 7,31.   
 
This large international survey included respondents from 53 different countries and 
involved a broad spectrum of stakeholders including a large number of patients and 
caregivers.  Using the Likert and BWS allowed us to determine absolute importance as well 
as prioritisation of the outcomes relative to each other.  Prioritisation is necessary to ensure 
that the most important and relevant outcomes are incorporated into a core outcome set. 
We were only able to translate the survey into one language other than English due to 
resource limitations which may have led to ascertainment bias but the participants were 
from a large number of countries covering a broad geographic and socio-economic range.   
The survey was administered online to ensure efficient dissemination and to minimize data 
transfer errors, however we recognize this restricted participation to those with access to 
the internet and computer literacy.   
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The results of this survey will contribute to our initiative to develop core outcome measures 
for cardiovascular disease for use in trials of people on haemodialysis.  Utilizing this survey 
will ensure that the core outcome set is representative of the shared priorities of patients, 
caregivers, clinicians, researchers, policy makers, and relevant stakeholders.  After achieving 
consensus on the use of these core outcomes it will be necessary to develop definitions that 
are valid for the haemodialysis population to ensure that trialists are able to report the 
outcomes consistently following an agreed standardised approach.   
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3.7 Figures and tables  
FIGURE 3.1 ABSOLUTE IMPORTANCE - PROPORTION OF PATIENTS/CAREGIVERS (RIGHT) 
  AND HEALTH PROFESSIONALS (LEFT) CONSIDERING OUTCOMES AS  
  CRITICALLY IMPORTANT, IMPORTANT OR OF LIMITED IMPORTANCE  
 
 
 
Critically important (black): 7-9 points on Likert scale; important (dark gray): 4-6 points on Likert 
scale; limited importance (light gray): 1-3 points on Likert scale 
PVD= Peripheral vascular disease 
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FIGURE 3.2  MEAN RELATIVE IMPORTANCE SCORES OF PATIENTS AND HEALTH 
PROFESSIONALS BASED ON THE BEST-WORST-SCALE.    
Ordered by the mean preference scores of patients/caregivers (bars with 95% confidence 
intervals). 
 
 
 
 
 
Bars represent mean preference score with 95% confidence intervals 
BWS – Best-Worst-Scale, PVD = Peripheral vascular disease 
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FIGURE 3.3 MEAN RELATIVE IMPORTANCE SCORES OF HEALTH PROFESSIONALS BY 
SURVEY LANGUAGE BASED ON THE BEST-WORST-SCALE.  
 
 
 
Bars represent mean preference score with 95% confidence intervals 
PVD = Peripheral vascular disease 
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TABLE 3.3 SUMMARY OF IMPORTANCE SCORES FOR PATIENTS/CAREGIVERS AND HEALTH PROFESSIONALS. 
 
Outcomes 
Median Mean Mean difference Proportion (%) 
critically 
important (7-9) 
Mean  
Likert score Likert score  Likert BWS score  
Patients/Carers HP Patients/Carers HP 
    Patients/ 
HP 
Patients/ 
HP 
  P value Carers Carers 
Sudden Cardiac Death 9 9 8.1 8.4 -0.3 0.03 87.9 93.1 6.2 9.0 
Heart attack 9 9 8.3 8.4 -0.1 0.45 90.3 94.4 5.9 7.7 
Stroke 9 9 8.2 8.1 0.1 0.64 89.9 89.6 5.3 6.0 
Heart failure 9 9 8.1 8.3 -0.1 0.34 93.2 93.5 4.9 6.8 
Thrombosis 8 8 7.9 7.7 0.2 0.13 88.4 83.4 3.3 3.6 
Valve replacement 8 7 7.4 6.8 0.6 <0.001 73.5 59.8 3.0 1.5 
Revascularization 8 8 7.6 7.6 0.0 0.99 74.0 81.3 3.0 4.0 
PVD 8 8 7.5 7.3 0.1 0.34 76.9 74.5 1.8 2.3 
Arrhythmia 7 8 7.2 7.6 -0.3 0.02 67.0 81.2 1.3 3.4 
Angina 7 8 7.2 7.4 -0.2 0.2 72.1 73.4 1.0 2.8 
 
HP – Health professionals PVD – Peripheral vascular disease  
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CHAPTER 4   
ESTABLISHING CORE CARDIOVASCULAR OUTCOME 
MEASURES FOR TRIALS IN HAEMODIALYSIS: REPORT 
OF AN INTERNATIONAL CONSENSUS WORKSHOP 
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4.1 Abstract 
Cardiovascular disease (CVD) affects more than two-thirds of patients on 
haemodialysis, is the leading cause of death in this population and yet, CVD outcomes 
are infrequently and inconsistently reported in trials in patients receiving 
haemodialysis. As part of the Standardised Outcomes in Nephrology-Haemodialysis 
(SONG-HD) initiative, we convened a consensus workshop to discuss the potential use 
of myocardial infarction (MI) and sudden cardiac death (SCD) as core outcome 
measures for CVD for use in all trials in people on haemodialysis.   Seven 
patients/caregivers and 51 health-professionals from 15 countries discussed selection 
and implementation of the proposed core outcomes. Five main themes were 
identified. Capturing specific relevance to the haemodialysis population acknowledging 
prevalence, risk, severity, unique symptomology and pathophysiology. The dilemmas in 
using composite outcomes were recognised. Addressing challenges in outcome 
definitions, establishing a common definition, and addressing uncertainty in the utility 
of biomarkers in haemodialysis. Ensuring a meaningful metric for decision-making to 
facilitate comparison across trials. Enabling and incentivising implementation by 
ensuring cardiologists are involved in development and integration of the outcome 
measure into registries, trial-design and reporting guidelines. Based on these themes, 
participants supported the use of MI and SCD as core outcomes of CVD to be reported 
in all haemodialysis trials.  
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4.2 Introduction 
Cardiovascular disease (CVD) affects more than two thirds of people on haemodialysis 
and is the leading cause of death in this population1,2. CVD also increases their short 
and long-term morbidity in this population2. Traditional risk factors for CVD, including 
diabetes mellitus, hypertension and dyslipidaemia, are highly prevalent in the 
haemodialysis population3 and may act synergistically with non-traditional risk factors 
including uraemic toxins, electrolyte and fluid imbalance, disordered bone and mineral 
metabolism and haemodialysis modality 4-8. Optimal management of CVD in patients 
on haemodialysis remains uncertain. Evidence from trials to inform decisions is 
currently limited because patients on haemodialysis are often excluded from 
cardiovascular trials 9. Furthermore, cardiovascular outcomes remain infrequently 
reported, appearing in only 12% of trials in haemodialysis 10. 
 
There is considerable heterogeneity as well as extensive use of surrogate and 
composite cardiovascular outcomes across trials in haemodialysis 11. In a recent 
systematic review of 175 trials in haemodialysis, over 230 measures were used for 26 
cardiovascular outcomes such as myocardial infarction, stroke and cardiac arrest 12. 
The three most frequently reported outcomes were serum biomarkers (excluding lipids 
and traditional cardiac biomarkers), cardiovascular composites, and serum lipids 11. 
Composite outcomes were highly variable with more than 50 different composite 
combinations used, with most combinations used only in a single trial 11.  The differing 
degrees of clinical impact of the individual outcomes incorporated into a composite 
outcome as well as the difficulty in comparing composites across trials makes 
estimates of the comparative effectiveness of interventions highly uncertain. This in 
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turn, hinders progress towards improving cardiovascular morbidity and mortality in 
this high-risk population.   
 
Surrogate markers of CVD, both biochemical (e.g. lipids) and anatomical (e.g. left 
ventricular mass index), are also frequently used in cardiovascular trials and yet they 
may not accurately predict the effect of an intervention on important clinical 
outcomes such as sudden cardiac death, myocardial infarction or stroke 13,14, nor are 
they meaningful to patients to support decision-making 15. CVD has been prioritised by 
patients, caregivers and health professionals as a critically important outcome for use 
in all trials in haemodialysis 16. Specifically, cardiovascular events such as myocardial 
infarction, sudden cardiac death and stroke, which have direct impact on patients in 
terms of symptoms and quality of life and survival, and yet these outcomes were 
reported in less than 10% of trials that report CVD outcomes in haemodialysis 11. 
 
These problems with outcome reporting have driven efforts to develop core outcome 
sets, defined as an agreed standardised set of outcomes that should be measured and 
reported, as a minimum, in all clinical trials in specific areas of health or health care 17. 
This is a two-step process requiring the identification of the domain, such as 
myocardial infarction, followed by determining the metric(s) that best defines that 
domain, such as ECG and cardiac enzyme.  In cardiovascular medicine, core outcome 
sets are being developed in specific populations including pregnant women with CVD 18 
and patients undergoing cardiac surgery 19. In cardiac surgery the core outcome set 
consists of mortality, quality of life, hospitalisation and cerebrovascular complications 
20. The American Heart Association has developed key data elements and definitions 
for cardiovascular endpoint events in clinical trials, electrophysiological studies and 
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procedures reporting and a cardiovascular vocabulary for electronic health records 21-
23. Collectively, these efforts endeavour to improve consistency and relevance of 
cardiovascular events reported in the general population. 
 
Recently, the Standardised Outcomes in Nephrology Haemodialysis (SONG-HD) 
initiative was launched to establish a set of core outcomes for trials in haemodialysis. 
Based on a consensus process involving more than 1200 patients, caregivers and 
health professionals from over 70 countries, CVD (together with vascular access, 
fatigue and mortality) was identified as a core outcome. As part of the SONG-HD 
Initiative to establish core outcome measures for CVD we administered an 
international survey to rank which CVD outcomes were the most important to all 
stakeholders24.  We then convened a consensus workshop in New Orleans in 
November 2017 during the American Society of Nephrology Kidney Week Conference 
with patients, caregivers, and health professionals to discuss the identification and 
implementation of a core outcome measure for CVD to be reported in all trials in 
haemodialysis populations. This report provides a summary of the workshop 
discussion and outlines recommendations for establishing core CVD outcome 
measures in haemodialysis. 
 
4.3 SONG-HD Cardiovascular Disease Consensus Workshop 
Context and scope 
The SONG-HD Cardiovascular Disease consensus workshop was held on November 1st, 
2017 in New Orleans, USA in conjunction with the American Society of Nephrology 
Kidney Week Conference 2017.  The workshop brought together stakeholders 
(patients, caregivers, and health professionals) to discuss the identification and 
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implementation of a core outcome specifically for CVD to be reported in all 
haemodialysis trials. Based on a systematic review 11 and interim results from an 
international survey on CVD outcomes completed by patients/caregivers and health 
professionals prior to the workshop, the two prioritised cardiovascular outcomes were 
myocardial infarction and sudden cardiac death. These potential core cardiovascular 
outcomes were presented to stakeholders for discussion.  
 
Participants and contributors 
Patients, caregivers and patient representatives with experience of haemodialysis, and 
health professionals (nephrologists, cardiologists, nursing and allied health 
professionals, researchers, trialists, regulators, funders, and policy makers) were 
invited to the workshop. Invitations were also extended to representatives of 
professional societies (e.g. American Society of Nephrology), regulatory agencies (e.g. 
Food and Drug and Administration [FDA], Centers for Medicare and Medicaid Services 
[CMS]), journal editors, registries, funding organisations (e.g. National Institutes for 
Health [NIH]), industry, and guideline organisations (e.g. Kidney Disease Improving 
Global Outcomes).   
 
Workshop program and materials 
The workshops materials were circulated to all investigators two weeks prior to the 
workshop. The materials included an overview of the SONG-HD process, results of the 
systematic review of cardiovascular outcomes in haemodialysis trials, and interim 
results of an international online survey with patients/caregivers and health 
professionals who ranked the importance of cardiovascular outcomes (e.g. myocardial 
infarction, sudden cardiac death) to be reported in trials in haemodialysis. We also 
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included definitions of myocardial infarction currently used including the Third 
Universal Definition 25 and the definitions used in a number of landmark cardiovascular 
trials in patients with end-stage kidney disease (ESKD) 26-29.   
 
Participants were allocated to one of six break-out discussion groups with 7-10 
members. Each group had at least one patient/caregiver. The groups were facilitated 
by EO, AKV, JCC, WW, AL and DW. The facilitator asked participants to discuss: the 
interim results of the survey (which is beyond the scope of the current report and will 
be published separately); the potential use of myocardial infarction and sudden cardiac 
death as core outcome measures including the definition, feasibility, validity and 
discrimination; how they should be reported, including metric, comprehensibility for 
patients; and implementation. In the plenary session, one member from each group 
presented the main points of their discussion. The Chair of the workshops (DCW) 
summarised the presentations across the groups. The group discussions and the 
plenary sessions were audio-taped and transcribed. 
 
The transcripts were entered into HyperRESEARCH (ResearchWare Inc. United States; 
Version 3.0.) to facilitate coding and analysis of the data. The first author (EO) coded 
the transcript line-by-line and inductively identified concepts relating to the 
identification and implementation of a core outcome measure for CVD to be reported 
in trials in haemodialysis. All participants and contributors received a draft workshop 
report to provide feedback within a two-week timeframe to ensure that the findings 
reflected participants’ perspectives. Additional comments were integrated into the 
final report. 
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In total, 51 healthcare professionals (nephrologists, cardiologists, nursing and allied 
health professionals, researchers [including trialists], journal editors, policy makers and 
industry representatives) and seven patients/caregivers attended the workshop. The 
participants were from 15 countries. Additional investigators who were unable to 
attend (n=58) contributed feedback on the workshop program and the draft workshop 
report by email. 
 
4.4 Summary of the workshop discussion 
We identified five main themes (Figure 4.1): capturing specific relevance to the 
haemodialysis population; dilemmas in using composite outcomes; addressing 
challenges in outcome definition; ensuring a meaningful metric for decision-making; 
and enabling and incentivising implementation. The respective subthemes are 
described below. Selected illustrative quotations for each theme are shown in Table 
4.1. Recommendations from the workshop discussions are summarised in Figure 4.2. 
 
Capturing specific relevance to the haemodialysis population  
“It’s a different conversation with somebody on dialysis, and I don’t believe that that’s 
always acknowledged, that dialysis patients are unique. Not just in their risk factors 
[for CVD], but in how they can and should be treated and take care of themselves.” 
(Health professional, Group 3) 
 
Prevalence, risk and severity of the cardiovascular outcome:  Participants considered 
whether the core CVD outcome should be based on prevalence in the haemodialysis 
population (i.e. myocardial infarction), its specificity to a haemodialysis population (i.e. 
sudden cardiac death) or the impact of the outcome to patients (i.e. heart failure or 
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stroke), “There is a difference between importance versus frequency” (Health 
professional, Group 1). The relevance of the CVD outcomes was argued to be 
fundamental to the decision – “I’m okay with the fact that it’s [myocardial infarction] 
the most frequently measured, but I’m not okay with the fact that probably it’s not 
really the most relevant” (Health professional, Group 1).  
 
Complex symptomology and diagnosis: It was emphasised that CVD in a patient on 
haemodialysis did not often present in a classical way, and the ability to diagnose CVD 
in the haemodialysis population was particularly difficult. Heart failure could be 
misdiagnosed in a patient with fluid overload, a myocardial infarction could be missed 
in a patient without chest pain, and a sudden cardiac death could be misclassified as a 
myocardial infarction. The core outcome measure for CVD had to be carefully 
established for the specific population, “that sudden cardiac death in someone who is 
on dialysis, if you were to use the general population term, probably you would think 
this is a myocardial infarction death. When in actual fact you realise in the years that 
pass that actually a very large proportion may not be myocardial infarction” (Health 
professional, Group 3). 
 
Considering consequences on quality of life:  CVD could impact quality of life, which 
was a key consideration as patients “want to be able to survive and have some 
semblance of quality of life” (Health professional, Group 2). Stroke and heart failure 
were highlighted as having a potentially more severe and immediate impact on 
function and overall quality of life day-to-day.  “Most of my patients put a stroke 
ahead of everything, ahead of sudden cardiac death, myocardial infarction, because 
it’ll be the thing with the most obvious change in quality of life because it’s immediate” 
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(Health professional, Group 2). However, silent or recurrent myocardial infarction was 
felt to contribute to long term poor outcomes and quality of life, “you were saying 
about quality of life and heart failure, it [myocardial infarction] is crucial in the 
development of heart failure and it does impact on functional cardiovascular reserve, 
so it is sensitive to have it in there because it will ultimately impact adversely on 
function.” (Health professional, Group 2)  
 
Accounting for geographic variation: The variation in prevalence of CVD across 
countries was recognised – “Like in Japan, strokes are a lot more common [than MI]." 
(Health professional, Group 4). Treatment could vary depending on the healthcare 
context – “hospitalisation is region-dependent, because in some regions, patients are 
going to be hospitalised earlier than in other regions” (Health professional, Group 5). A 
core outcome for CVD in haemodialysis had to be feasible to measure internationally, 
for example “countries around the world where you cannot measure troponin” (Health 
professional, Group 6). 
 
Having potential for intervention: There was some concern that establishing a core 
outcome in CVD may drive research in a futile direction, particularly if they expected 
there to be little potential for interventions to change the outcome – “MIs, heart 
attacks are clearly important. My concern is that by reporting them in every trial, 
they’re so poorly modifiable that it’s not going to get us where we want to go in terms 
of getting better, patients better at the end of the day” (Health professional, Group 5).  
It was speculated that sudden cardiac death and heart failure might be more 
modifiable than myocardial infarction. Participants realised that trialists may not want 
to include an outcome which is unlikely to be responsive to their particular 
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intervention but agreed that outcomes of critical importance to patients and clinicians’ 
decision making should still be measured and reported, irrespective of whether they 
may respond to the intervention.        
 
Dilemmas in using composite outcomes  
Obfuscation and misinterpretation of findings: For a core CVD outcome, “having a 
composite outcome would be very complex” (Health professional, Group 4). The 
combination of outcomes used in composites (presented during the workshop) was 
extremely heterogenous, making comparisons across trials impossible – “it would be 
great if everybody used the same definition of MACE and MACE-plus.....even 
imperfect, at least we could compare results” (Health professional, Group 4). Issues 
discussed also included: the potential to “cherry pick” components for a composite 
cardiovascular disease outcome in the attempt to demonstrate a positive effect for an 
intervention, and combining outcomes of varying prevalence and importance to 
patients could dilute the relevance of the results, and be potentially misleading. For 
these reasons, it was “not actually appropriate to combine [outcomes], or it may not 
be smart to do so [for a core outcome]” (Health professional, Group 4). Reporting an 
individual specific CVD outcome would make results more transparent and thus 
preferable as a core outcome.  
 
Benefits to trialists: It was acknowledged that “as much as we might not want to 
encourage the use of a composite endpoint, the reality is regulatory agencies, that’s 
exactly what they demand” (Health professional, Group 5). The use of composite 
outcomes could reduce cost by reducing the required sample size – “you have to have 
a composite outcome in order to have statistical significance with a smaller sample 
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size” (Health professional, Group 5). Some thought it may be important to report more 
than one CVD outcome, and to “try and define what the composite outcome should 
be” (Health professional, Group 5).  
 
Addressing challenges in symptomatology, definition and utility of outcomes  
Consistency, applicability and specificity of definitions: Given the wide heterogeneity in 
definitions for cardiovascular outcomes in trials, establishing a consistent definition 
was thought to be paramount. There were conflicting views on the current definitions 
available: The Third Universal definition for myocardial infarction was suggested as a 
gold standard and whilst  “there’s a strength in a gold standard if you will, that is 
internationally accepted; rather than reinventing the wheel and defining this from 
scratch which may take decades” (Health professional, Group 6), some health 
professionals argued that the current definition had  “to be adapted for the 
haemodialysis population” (Health professional, Group 3). This was on the basis of the 
different symptomatology and diagnostic criteria in haemodialysis: “they often don’t 
have pain, so that’s the first criteria. Their troponin’s elevated anyway, that’s the 
second criteria, troponin’s up at baseline in many patients, no?” (Health professional, 
Group 2); and that “the type-2 MI is predominant, not the type-1” (Health 
professional, Group 4). The definition had to be practical, comprehensible to patients, 
and validated in the haemodialysis population, “it’s good to be adapted, it’s more 
important to be validated” (Health professional, Group 3).  
 
Recognising variability in symptoms: In the haemodialysis population, the symptoms of 
MI and heart failure differed, “I didn’t have a sharp pain, but I had difficulty breathing 
and stuff like that” (Patient, Group 3). A health professional further explained, 
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“because in our population, a lot of the heart attacks are actually silent, so actually it’s 
quite different from the general heart attack that we see in the usual population. Most 
patients may manifest heart failure rather than classical heart attack symptoms or 
chest pain. That is one important consideration when you diagnose a heart attack in a 
classical way where you need to have the symptoms, chest pain” (Health professional, 
Group 4). It was also difficult to differentiate heart failure from fluid overload in 
haemodialysis. 
 
Uncertainty in the clinical utility of biomarkers specific to haemodialysis: The 
limitations of biomarkers in haemodialysis were recognised – “biomarkers which are 
very useful in general population cannot be truly interpreted in renal patients” (Health 
professional, Group 6). Troponin levels were not standardised in a haemodialysis 
population and each assay and lab performs differently. The timing of a biomarker, 
whether it was before or after dialysis and what constituted a significant change in 
troponin levels was uncertain in the context of haemodialysis – “we don’t know what a 
significant delta is, right?” (Health professional, Group 1). 
 
Clarity for adjudication: The definition of the core CVD outcome in haemodialysis had 
to have potential for use not only by clinicians as a diagnostic tool but also by trialists 
and registries, “frankly the definition comes a bit too late. It’s already been defined by 
the local doctor” (Health professional, Group 4). The ability to use the definition in the 
context of clinical care and in trials was suggested to align outcome ascertainment 
based upon clinical diagnosis and by trial outcome adjudicators, “It turns out only 
about two-thirds to three-quarters of what the investigators reporting as an MI is 
finally adjudicated positively as an MI … you’re limited in your data that you get in a 
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clinical trial setting, because often times heart attacks are happening in the hospital. 
The investigator’s not there, and you’re limited by the data that you’re getting” (Health 
professional, Group 4).  
 
Selecting a meaningful metric for decision-making 
Comprehensible and meaningful to patients: The core outcome for CVD had to be 
simple and readily understood by patients so that it could inform decision-making, “I 
wonder whether the definition of ‘heart attack’ to a patient is different as well, 
whether any condition involving the heart, including sudden cardiac death that we 
define differently, could mean heart attack for patients” (Health professional, Group 
1). “The simpler you can make it for the average patient the better, because remember 
when you’re giving them information; the vast majority of them are being 
overwhelmed by the process itself” (Health professional, Group 2). Patients and 
caregivers wanted to be told the specific risks of CVD, “I’d rather know the numbers 
and know the facts so that I can do my best to prevent that [myocardial infarction] 
from happening to me.” (Patient, Group 2). Some suggested providing information in a 
visual format and to “use numbers, not percentages when describing anything” 
(Patient, Group 6) and “you should always be grounded in the absolute [risk]” (Patient, 
Group 6).  Personalising cardiovascular risk was important to patients, “there’s ways of 
putting it that you give that information, and yet you’re actually personalising it as 
well” (Patient, Group 2).   
 
Distinguishing severity and recurrence: The outcome measure for CVD needed to 
capture the severity of an event, mainly in terms of its clinical consequences and 
impact on quality of life, “you could have someone who has a very large MI and 
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develops heart failure and other complications, arrhythmias, and then you can have 
another patient who meets the criteria but just squeaks by and doesn’t have a lot in 
terms of effects, in terms of quality of life, and in terms of function” (Health 
professional, Group 5).  The outcome measure should capture severity by defining a 
clear threshold after which the event fulfils the definition.  “If we want to assess 
severity at the same time, it has to have some sort of a consequence, either needing 
an intervention or needing hospitalisation” (Health professional, Group 5) and trialists 
may want to add this outcome to the core outcome. The recurrence of events also had 
to be considered – “it matters to people if they had one heart attack or three” (Group 
6), though the same definition could be used by trialists to capture recurrence.   
 
Comparability across trials: A single metric would facilitate ease of comparison across 
trials.  Some particular metrics may lead to further inconsistencies. For example, CVD-
related hospitalisation would lead to undue variability across trials because 
“hospitalisation is region-dependent; in some regions patients are going to be 
hospitalised earlier than in other regions” (Health professional, Group 5). Using a time-
to-event metric may be simpler and would mean that “you could still infer your 
proportion of events. You could extract whatever other metric you want” (Health 
professional, Group 2), however this would miss subsequent events. Ultimately the 
metric should facilitate collection of a minimum dataset with minimal flexibility 
because “if we say leave it to trialists, we’ll just get the same mess we’ve got now” 
(Health professional, Group 2).  
 
Enabling and incentivising implementation 
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Integration into registries: Recognising the growing interest in conducting registry-
based trials to increase efficiency and reduce the burden to trialists, the core outcome 
measure had to be applicable and feasibly integrated in registries across healthcare 
contexts - “to do more efficient trials....to build your outcome measures so they can be 
used across borders as in across different healthcare systems” (Health professional, 
Group 4).   
 
Incorporating into clinical care: The definition for the core CVD outcome had to be 
readily embedded into routine clinical care, “definitions for MI which we could 
standardise in administrative data sets” (Health professional, Group 6) then “if this was 
adopted by regulators or registry trials, ....healthcare systems or registry systems could 
participate, and may actually have an incentive to be competitive and implement [the 
definition] into the clinical, everyday care setting” (Health professional, Group 6).  
 
Seeking authoritative endorsement: Buy-in and endorsement by journals and 
guidelines would support implementation of the core outcome measure for CVD, 
incorporating them into trial reporting guidelines “just as journal editors now require a 
CONSORT diagram, perhaps we could convince the journal editors that using standard 
definitions is also going to be important to be published in that particular journal” 
(Health professional Group 5).  It also requires uptake by those involved in trial design, 
“bring in some of the thought leaders that design these trials, you need to bring in the 
regulatory agencies. They all need to come together and hash it out, and comment on 
the feasibility of doing this and the appropriateness of doing this. If you don’t have the 
buy-in from those who are designing the trials, you don’t have the buy-in in the 
regulatory agencies, it’s not going to happen” (Health professional, Group 4). They 
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questioned, “how much is [the core outcome measure to be used as] a guideline, how 
much is it something we aspire to, and how much is going to be mandated?” (Health 
professional, Group 6), and some contended that the measure should be compulsory 
to ensure uptake, “prescriptive is usually the best vehicle towards implementing and 
making change happen” (Health professional, Group 6). They suggested to: “[make] it 
be part of the requirements for FDA approval, that trials have actually measured these 
core outcomes?”(Health Professional, Group 5). They thought it would be similar to 
implementing “mandatory trial registration, everybody was like, ‘Ugh, this is horrible. 
It’s so much extra work,’ and now we don’t think twice. We just do it.” (Health 
professional, Group 6)  Alternatively an “opt in” system could be considered, “maybe 
provide a checklist that investigators have to [fill in]” (Health professional, Group 5). 
 
Requiring cardiology input and buy in: Cardiologists needed to be integrally involved in 
the development of the core outcome measure for CVD in haemodialysis to support 
implementation – “it’s of great value to have an expert group of cardiologists look at 
these things (Health professional, Group 4) so the measure would be “accepted into 
the cardiology community” (Health professional, Group 1). The involvement of 
cardiologists would facilitate acceptance and ensure that both nephrology- and 
cardiology-led trials could be effectively compared and would be relevant to the 
haemodialysis population, “It would be very difficult to extrapolate anything if we 
don’t have a common language with the cardiologists” (Health professional, Group 1).  
 
4.5 Discussion 
Core outcomes for CVD should reflect what is most important and relevant to patients 
on haemodialysis and their clinicians. Myocardial infarction and sudden cardiac death 
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were agreed upon as the most important CVD outcomes to report in haemodialysis 
trials. CVD outcomes such as heart failure and stroke were recognised as important but 
consensus was achieved for myocardial infarction and sudden cardiac death for a 
number of patient-centred, clinical and pragmatic reasons. They are of high 
importance to patients and health professionals, and there is an increased risk in and 
are of specific relevance to patients on haemodialysis. Myocardial infarctions were 
believed to contribute to heart failure and participants felt that heart failure (due to 
the difficult clinical distinction from fluid overload) and stroke (due to the extensive 
investigations required to accurately diagnose) would not be simple outcomes to 
adjudicate in people on haemodialysis. Myocardial infarction is particularly relevant 
because it is associated with high mortality, functioning, quality of life, and had long-
term health and psychosocial consequences in patients on haemodialysis.  
 
Composite outcomes are frequently used in cardiovascular trials, because they can 
minimise resources and increase power in a trial. However, they should not be used as 
core outcomes because of the challenges they pose for interpretation of the findings. 
Even the frequently used composite endpoint “Major adverse cardiovascular events 
(MACE)” demonstrates substantial heterogeneity in the study-specific individual 
outcomes used to define MACE, with substantially different results and conclusions 
across trials 30. A recent systematic review found similar heterogeneity across other 
CVD composite endpoints used in trials in haemodialysis 12. The CVD core outcomes 
should be simple and the data for the outcomes should be able to be collected in all 
trials in haemodialysis regardless of the intervention. Using well-defined individual 
CVD outcomes would therefore be preferable to a composite when selecting core 
outcomes for CVD in trials in haemodialysis.  
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As recognised by the workshop attendees, defining the core outcomes would be 
difficult given that current definitions for CVD outcomes in the general population 
could not be readily extrapolated and applied in patients on haemodialysis. This is 
because of the variability in clinical presentation of CVD, uncertainty in the clinical 
utility of CVD biomarkers, and problems with the interpretation of diagnostic tests in 
the haemodialysis population.  
 
Myocardial infarction and sudden cardiac death are not only frequent events in HD, 
these outcomes have specific relevance to the haemodialysis population. Patients on 
dialysis are more likely to die during hospitalisation for acute MI than patients with 
normal kidney function 31 and one year mortality following acute myocardial infarction 
approaches 60% in patients with ESKD 32 compared to less than 10% in the general 
population 33,34. Sudden cardiac death accounts for nearly 30% of all-cause mortality in 
prevalent haemodialysis patients and around 35% of all-cause mortality in patients 
initiating dialysis 2,35. The annual risk of sudden cardiac death is almost three-fold 
higher in haemodialysis patients (5-7%) compared to the general population (1.5-2.7%) 
36.  
 
There are several challenges in defining myocardial infarction and sudden cardiac 
death for the haemodialysis population. The current components of the Fourth 
Universal definition of myocardial infarction includes symptoms, biomarker increments 
and ECG changes37. These may not always apply to people on haemodialysis because 
chest pain is not always present in patients on haemodialysis and troponin levels can 
be raised at baseline and altered by haemodialysis. A specialist group will be convened 
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to determine how the Fourth Universal definition can be used or adapted in the 
haemodialysis population. The heterogeneity in the events ascribed to sudden cardiac 
death, particularly in the haemodialysis population, also poses a major challenge. The 
recent Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference 
on Chronic kidney disease and arrhythmias similarly highlighted the need to refine the 
definitions of sudden cardiac death in ESKD patients, emphasising the unexpected 
nature of sudden death to avoid misclassifications. This international group have 
proposed definitions of sudden death, sudden cardiac death, and aborted cardiac 
arrest pertinent for ESKD patients 36.  
 
Both outcome measures require a meaningful and simple metric to allow 
comparability across trials. Implementation of core outcomes for CVD in haemodialysis 
trials would require input from cardiologists and support from registries, guidelines, 
journals; and should be feasibly implemented in routine clinical practice. 
The consensus workshop was conducted in English and therefore potentially limited 
input from non-English speaking participants.  However, representatives from 15 
countries, both developed and developing, attended the workshop which we hope 
does make our work more generalisable.  
 
Recommendations from the workshop are summarised in Figure 4.2.  To address the 
challenges in the measurement of the core outcomes myocardial infarction and 
sudden cardiac death, an expert working group will be convened to derive universally 
agreed upon definitions for use in the haemodialysis population. These definitions will 
need to be globally feasible and of minimal burden to implement in trials. Making 
these definitions as pragmatic as possible will support implementation. These 
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measures will need to be assessed based upon the Core Outcome Measures in 
Effectiveness Trials (COMET) criteria including content and structural validity, 
responsiveness and measurement error 38 and then validated by using them as 
outcome measures in historical trials to ensure they are fit for purpose. The ability to 
accurately compare data across trials using core CVD outcomes will optimise shared 
decision making and likely contribute to improved cardiovascular morbidity and 
mortality in this very high risk population.  
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4.7 Figures and Tables 
FIGURE 4.1 SUMMARY OF THEMES DERIVED FROM THE CONSENSUS WORKSHOP  
HD-haemodialysis, ESKD – end stage kidney disease 
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into clinical care can never match in a registration trial being a registry trial, but still. Let’s assume 
that they do so, then actually healthcare systems or registry systems participate, 
may actually have an incentive to be competitive to implement that in the clinical, 
everyday care setting. (Group 6, health professional) 
Definitions for MI we could standardize in administrative data sets, so it might be 
an opportunity for more of that. (Group 6, health professional) 
Seeking 
authoritative 
endorsement 
Should it be part of the requirements for FDA approval, that trials have actually 
measured these core outcomes? (Group 5, health professional) 
How much is it a guideline, how much is it something we aspire to, and how much is 
going to be mandated. That’s an important issue. (Group 6, health professional) 
Being prescriptive is usually the best vehicle towards implementing and making 
change happen. An example that was mentioned earlier was mandatory trial 
registration at the time when clinical trials registration became mandatory, 
everybody was like, ‘Ugh, this is horrible. It’s so much extra work,’ and now we 
don’t think twice. We just do it. (Group 6, health professional) 
Requiring 
cardiology input 
and buy in 
We should bring all the stakeholders to the table. You need to bring the 
cardiologists to the table, you need to bring not only the MI, but the heart failure 
and whatever else is going to be in the composite. You need to bring in some of the 
thought leaders that design these trials, you need to bring in the regulatory 
agencies. They all need to come together and hash it out, and comment on the 
feasibility of doing this and the appropriateness of doing this. Because if you don’t 
have the buy-in from those who are designing the trials, you don’t have the buy-in 
in the regulatory agencies, it’s not going to happen. (Group 5, health professional) 
Approach the cardiologists and maybe to become a stakeholder in the process [of 
writing the next Universal Definition], and make sure that the kidney perspective 
gets heard and potentially implemented in future iterations of it. (Group 6, health 
professional) 
It’s of great value to have an expert group of cardiologists look at these things, 
because even they tend to disagree sometimes, and at least what you have finally is 
a consensus opinion. (Group 4, health professional) 
Abbreviations: CKD – chronic kidney disease; ECG – electrocardiogram; FDA – Food and 
Drug Administration. 
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CHAPTER 5   
INCIDENCE OF ISCHAEMIC HEART DISEASE IN MEN AND 
WOMEN WITH END-STAGE KIDNEY DISEASE:  A COHORT 
STUDY 
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5.1 Abstract  
Background: The incidence of ischaemic heart disease (IHD) has fallen consistently in the 
general population; attributed to effective primary prevention strategies.  Differences in 
incidence have been demonstrated by sex.  Whether this fall in incidence and sex differences 
is mirrored in people with end stage kidney disease (ESKD) is unclear.  We aimed to establish 
the relative risk of IHD events in the ESKD population. 
Methods: We performed a retrospective cohort study from 2000-2010 in people with ESKD 
in New South Wales.  We performed data linkage of the Australia and New Zealand Dialysis 
and Transplant Registry and state-wide hospital admission and death registry data and 
compared this to general population data.  We calculated incidence rates, incidence rate 
ratios (IRR), and time-trends using indirect standardisation by IHD event.   
Results: 10,766 participants, contributed 44,149 years of observation time. Incidence rates 
were substantially higher than the general population for all IHD events (any IHD event: IRR 
1.8, 95% confidence interval (CI) 1.7-1.9 for men, IRR 3.4, 95%CI 3.1-3.6 for women).  Excess 
risk was higher in younger people (age 30-49 IRR 4.8, 95%CI 4.2-5.4), and in women with a 
three-fold increase risk overall and nearly a ten-fold increase in risk in young women (female 
age 30-49 years: IRR 9.8 95%CI 7.7-12.3), results were similar for angina and acute 
myocardial infarction. IHD rates showed some decline for men over time, (ratio of IRR 0.93, 
95%CI 0.90-0.95) but were stable for women (ratio of IRR 0.97, 95%CI 0.94-1.01). 
Conclusions: People with ESKD have substantially higher rates of IHD than the general 
population, especially women, in whom no improvement appears evident over the past 10 
years.  
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5.2  Introduction 
Ischaemic heart disease (IHD) is the most common of all cardiovascular diseases and globally 
is the leading cause of death1,2. The incidence and mortality from IHD in the general 
population in high income countries has steadily declined3,4. The decline in incidence has 
predominantly been ascribed to improvements in primary prevention strategies with 
reduced mortality due to improved medical management5-9.   In people with end stage 
kidney disease (ESKD) there is an increased prevalence of IHD and outcomes are poorer10,11. 
People receiving haemodialysis for ESKD who present with acute myocardial infarction (AMI) 
have greater in-hospital, and post discharge mortality, as well as higher recurrence rates and 
more readmissions12,13. 
 
The aetiology of IHD in the ESKD population is multifactorial with a more complex  
pathogenisis than that found in the general population14. In ESKD the pathogenesis is driven 
in part by conventional risk factors including dyslipidaemia, diabetes and hypertension but 
supplemented with ESKD-specific risk factors14,15. These include uraemic toxins and dialysis 
therapy itself, which collectively contribute to oxidative stress, inflammation, immune 
dysfunction, together with disorders of bone and mineral metabolism leading to increased 
vascular calcification14,16-18.    ESKD populations are often excluded from cardiovascular trials 
and there is paucity of evidence regarding the effectiveness of primary prevention strategies 
in the ESKD population19-21.  
 
In the general population, IHD is the largest contributor to cardiovascular mortality and 
morbidity for both men and women, however there are gender discrepancies. The most 
recent NHANES data suggest that the average annual rate of first cardiovascular event rises 
from 3 per 1000 men of 35 to 44 years of age to 74 per 1000 men of 85 to 94 years of age22.  
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For women, comparable rates occur 10 years later in life though the gap narrows with 
advancing age22.  Data from the Framingham Heart Study have shown that over the last two 
decades the prevalence of myocardial infarctions has declined in men in mid-life (35 to 54 
years)23.  Over the same time period the prevalence of myocardial infarction has increased in 
women in the same age group23,24.  Women have higher cardiovascular mortality rates than 
men, a difference partially ascribed to gender bias in the management of coronary heart 
disease and stroke in women25-28. A number of initiatives in the general population to 
address this imbalance have seen the cardiovascular death rate in women fall by nearly 
half29.   Whilst addressing the cardiovascular disease burden in the ESKD population became 
an international priority nearly 20 years ago it is unclear whether there has been 
improvement over time30,31.   The aims of this study were to describe the trends in incidence 
of IHD in the ESKD population compared to the general population, and to identify any 
gender or age group differences.   
 
5.3  Methods 
Study design and setting 
We performed a retrospective cohort study of all adults treated for ESKD in New South 
Wales (NSW), and compared them with the general population of Australia between July 1st 
2000 and June 30th 2010.  The study used data linkage, procedures for which have been 
reported previously32. NSW has a population of 7.4 million people, approximately one third 
of the total Australian population, and is demographically representative of the country. 
Study populations 
 
ESKD population:  NSW ESKD patients were identified from The Australia and New Zealand 
Dialysis and Transplant Registry (ANZDATA), which collects demographic, clinical and 
 Chapter 5: Incidence of IHD in ESKD 
102 
 
treatment data on all people requiring renal replacement therapy.    ANZDATA records co-
morbidities including diabetes, ischaemic heart disease, peripheral artery disease and 
cerebrovascular disease along with smoking history and cause of renal failure.    
 
To identify hospitalisation and death events in the ESKD population we linked ANZDATA 
records with the NSW Admitted Patient Data Collection and the NSW Registry of Births 
Deaths and Marriages (Appendix 2 Figure 1).  Admitted Patient Data Collection is a 
mandatory state-wide collection of all admitted patient services provided by public and 
private hospitals.  Key clinical information (including the principal and secondary diagnoses 
made during admission, coded according to the International Classification of Diseases, 10th 
revision Australian modification (ICD-10-AM) and health service utilisation (referrals and 
procedures) are recorded for every hospital discharge, death, or transfer.  By statute, a 
death certificate is completed by a doctor and returned to the Registry of Births, Deaths and 
Marriages for all deaths in NSW, and we obtained information on the date of death for 
cohort participants.  Data linkage (Appendix 2 Figure 1) was undertaken independently by 
the NSW Centre for Health Record Linkage using ChoiceMaker software. ChoiceMaker uses 
probabilistic linkage and achieves a false positive rate of around 5/1,000 and a false negative 
rate of around 5/1,00033. The Centre for Health Record Linkage complies with best-practice 
in privacy-preserving record linkage33.  Ethical approval was granted by the New South Wales 
Population and Health Services Research Ethics Committee (Approval Number 
2011/12/363).   
 
General population:  Data on hospitalisation were not available at the state level, so 
Australian general population data were obtained from the Australian Institute of Health and 
Welfare (AIHW) which compiles annual statistics for every episode of care provided in public 
 Chapter 5: Incidence of IHD in ESKD 
103 
 
and private hospitals in Australia.  Data are coded using ICD-10-AM. To calculate rates of 
hospital admission, population numbers were obtained with age and sex-stratified estimates 
of the entire Australian population from the Australian Bureau of Statistics, 2000 to 2010.  
 
Statistical methods 
The primary outcome measure was hospitalisation with any IHD event.    IHD event types 
were identified from hospitalisations with a principal admission diagnosis code of; “Angina” 
(ICD-10 AM code of I20), “Acute MI”(I21) and the composite “Any IHD”  defined as I20, I21 as 
well as “Other acute IHD” (I22), “Subsequent MI” (I23), “Certain complications after acute 
MI” (I24) and “Chronic IHD” (I25) ).     We included both incident and prevalent ESKD 
patients; time at risk was measured from date of first treatment for ESKD, or July 1st 2000 if 
they already had started dialysis before July 1st 2000, until their first of each IHD event, 
death, or June 30th 2010, whichever came first.  Incidence rate ratios (IRR with 95% 
confidence intervals CI) for comparison to the general Australian population were calculated 
using indirect standardization by age, sex and calendar year.  Using only incident patients, 
we estimated cumulative incidence for any IHD event after starting treatment for ESKD using 
Kaplan Meier method. For both prevalent and incident patients we examined event rates, 
testing for trends over time using the Mantel-Haentszel method.   For comparisons between 
people with ESKD who were admitted with IHD and those who were not, we performed t-
tests to examine continuous data and Chi squared tests to examine categorical data. 
 
5.4 Results 
Participants 
We included 10,766 participants, contributing 44,149 years of observation time. The 
characteristics of participants are described in Table 5.1.  There were 6,271 (58.3%) men and 
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4,495 (41.7%) women at commencement, with 4,540 (42.2%) dying during follow up.  Of 
those that died, 1,098 (24.2%) were documented as having had at least one admission with 
IHD.    The majority of participants were white (N=8902, 82.5%) with glomerulonephritis and 
IgA nephropathy as the most common causes for ESKD (N=3,301, 30.9%).  Haemodialysis 
(N=7,433, 69.0%) was the most frequently initiated treatment for ESKD.  Over the duration 
of the study 1,961 (18.4%) people with ESKD experienced at least one ischaemic heart 
disease admission.  Those with at least one admission with IHD were more likely to be older 
(mean difference 4.7 years older, p<0.001), men (p<0.001), smokers, both current and 
former (p<0.001), and had pre-existing coronary artery disease, peripheral vascular disease 
and diabetes (p<0.001). A total of 1, 910 (17.7%) participants received a kidney transplant 
and 10.4% of those transplanted were hospitalised for IHD at some point during the study.   
 
IHD events 
There were 1,961 participants admitted 4,133 times with an IHD event, (range 1-26 times) 
over the study period. The first IHD event resulting in hospitalisation was:  angina in 37.1%, 
acute MI in 38.7% and chronic IHD in 23.6% (Appendix 2 Table 1).  Cumulative incidence 
from starting treatment for ESKD of IHD for men at one year was 9.4% (95%CI 8.5 to 10.4%) 
at five years was 26.5% (95%CI 24.7 to 28.3%) and by eight years was 32.3% (95%CI 30.0 to 
4.7%). For women, the cumulative incidence at one year was 6.6% (95%CI 5.7 to 7.6%), at 
five years 21.2% (95%CI 19.2 to 23.3%) and by eight years was 26.6% (95%CI 24.0 to 29.5%).  
The majority of events occurred over the first few years following the commencement of 
treatment for ESKD (Figure 5.1a). These patterns were similar for acute MI and angina. 
The overall incidence rate of admission for any IHD event was 4,442 per 100,000 person 
years (95% CI 4,249 to 4,643).  For men the rate was 4,923 per 100,000 person-years (95% CI 
4,657 to 5,203/100,000) and for women it was 3,789 per 100,000 person-years (95% CI 
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3,520 to 4,078/ 100,000).  When compared to the general population, the relative rate in 
men with ESKD was over one and a half times that of the general population (IRR 1.8 95%CI 
1.7 to 1.9).  For women, the relative rate was substantially higher (IRR 3.4 95%CI 3.1 to 3.6). 
For both men and women, relative rates were highest in the younger age groups and 
steadily declined with increasing age (Figure 5.2, Table 5.2).  Risk was particularly high for 
younger women; for women with ESKD aged 30-49 the rate was nearly ten times that of the 
general population (IRR 9.8 95%CI 7.7 to 12.3) (Figure 5.3, Table 5.2).   Women with ESKD 
experienced higher event rates than women in the general population across all age groups 
but the difference diminished as age increased. 
 
Acute MI:  There were 1,532 (14.2%) people admitted with at least one acute MI (range 1-12 
admissions per person).  The overall event rate was 2,072 per 100,000 person years (95%CI 
1,947 to 2,206).  For men this rate was 2,289 (95%CI 2,117 to 2,474) and for women it was 
1,772 (95%CI 1,598 to 1,968) per 100,000 person years.  In both men and women this rate 
steadily increased with age, but the relative rates were much higher in the younger age 
groups, again particularly for women (Figure 5.3).   
 
Angina: There were 1691 (15.7%) people admitted with at least one episode of angina (range 
1-17 admissions).  The incidence rate for hospitalisation with angina was 1,987 per 100,000 
person years (95% CI 1,863 to 2,119 per 100,000 person-years).  For men the rate was 2,142 
(1,974 to 2,323/100,000) and for women it was 1,773 (1,596 to 1,970/100,000).  Rates in 
men increased until the age of 70 and then started to fall; in women rates continued to 
increase with age (Figure 5.3).   Both men and women with ESKD experienced higher event 
rates the general population (IRRs -men: 1.6, 95% CI 1.5 to 1.7 and women 2.9, 95%CI 2.6 to 
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3.2); again this rate steadily increased with age, but the relative rates were much higher in 
the younger age groups, again particularly for women (Figure 5.3, Table 5.2).   
 
Progress over time: 
Incidence rates over time, for any IHD event, differed between males and females (p=0.04).  
Rates were stable over the decade in the female ESKD population (RR 0.97 per year, 95%CI 
0.94 to 1.01), while for men there was a decline (RR 0.93 per year, 95% CI 0.90 to  0.95) . 
Rates of angina fell for both men (RR 0.88 per year, 95%CI 0.84 to 0.92) and women (RR 0.93 
per year, 95%CI 0.87 to 0.99), with no evidence of a difference between the sexes (p=0.17).  
For acute MI, rates were relatively stable; with no difference between the sexes (p=0.5): 
men (RR 1.01 per year 95%CI 0.97 to 1.05) and women (RR 1.04 per year 95%CI 0.98 to 1.10) 
(Figure 5.4). 
 
5.5 Discussion 
This large retrospective cohort study shows greatly elevated rates of ischaemic heart disease 
for people with ESKD compared to the general population.  The majority of these events 
occurred within three years of starting haemodialysis.  Compared to the general population, 
risk was much higher in the younger years, particularly for women.  For women between 30 
and 49 years the risk of an IHD event was nearly ten times that of the general population 
risk.  Over the duration of the study, rates decreased for men but have remained unchanged 
for women.  
 
For women with ESKD, the relative risk of cardiovascular disease compared to the general 
population is significantly higher than for men with ESKD. In the general population, 
cardiovascular risk may be under-recognised and undertreated particularly in women and it 
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may be that this effect is magnified in the ESKD population34. Under-recognition of IHD in 
women might be due to physicians perceiving a woman’s cardiovascular risk is lower than 
that of a man34.  It is also known that some preventative therapies such as aspirin and statins 
appear less effective in women than in men35-38.  It is less clear how well primary prevention 
strategies are applied or are effective in the ESKD population.  It is possible that the burden 
of cardiovascular risk is under recognised or perhaps under treated given the context of 
other life limiting disease. Patients with advanced CKD are routinely excluded from clinical 
trials testing cardiovascular disease interventions so evidence surrounding efficacy in the 
ESKD population is sparse, with even less information about efficacy by gender21.   The sex 
difference could also arise because the protection usually experienced by women in the 
general population is diminished by ESKD, perhaps mediated by hormonal differences.  In 
the general population, cardiovascular disease rates in women rise sharply following the 
menopause and this has led to a number of hypotheses suggesting the protective effect of 
oestrogen on lipid profiles and vascular remodelling. In women with ESKD there is altered 
gonadotrophin release and that cyclical variation in oestrogen levels is lost39.   Menopause 
occurs at a younger age among women with chronic kidney disease; the median age of 
menopause is 50–51 years in normal women and 47 years among women with chronic 
kidney disease40.  Reduced cycling and lower levels of oestrogen may result in reduced 
vascular protection in the younger age groups.   Hormone replacement therapy has been 
used in the general population for the prevention of cardiovascular disease in post-
menopausal women.  However, a recent Cochrane Systematic review found no evidence 
that hormone therapy provided any protective effect against death from any cause including 
death specifically from cardiovascular disease. Rather, in post-menopausal 
women, hormone therapy increased the risk of stroke and venous thromboembolic 
events41.   
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Our study highlights IHD risk at a younger age for people with ESKD. It is possible that 
preventative strategies are not instituted early enough in the course of CKD, given the 
accelerated vascular pathology experienced as early as chronic kidney disease stage three. 
Clinical practice guidelines do not encourage early therapy; KDIGO guidelines from 2013 
recommended treatment with statin for adults of at least 50 years of age with an estimated 
glomerular filtration rate less than 60 mL/minute per 1.73 m2 when not treated with chronic 
dialysis or kidney transplantation.    It might also be that current preventative strategies are 
not efficacious.  The different pathophysiology involved in cardiovascular disease in ESKD 
together with the routine exclusion of patients with advanced CKD from most clinical trials 
testing CVD preventative therapies creates an evidence gap.  
 
Decrease in IHD over time for men suggests some progress preventing IHD in the ESKD 
population.  However, that same trend is not apparent in women with ESKD; with the 
magnitude of this difference being much greater than in general population epidemiology. 
The Framingham heart study gave higher weighting to men when calculating cardiovascular 
risk and this score has been used for over 20 years.  This has now led to better recognition of 
risk in men and over time a reduction in event rate.  A decade on, these improvements are 
now being reflected in the ESKD population.  Research collecting population-representative 
Australian data in 2008, documented gender disparities in the assessment and management 
of cardiovascular disease in primary care34. Education strategies regarding risk of 
cardiovascular disease in women in the general population have been employed more 
recently but whether with lag time this will be reflected in a reduction in event rate is yet to 
be seen.  
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This is a large cohort with a follow up duration sufficient to evaluate the outcomes of 
interest with reasonable precision.  The ANZDATA registry is also population based, which 
increases the generalisability of our results.  This study is consistent with cerebrovascular 
disease as the outcome of interest; people with ESKD had a substantially higher risk of 
stroke, again particularly in women and young people42. There are some potential 
limitations. Data linkage has inherent weaknesses, particularly when using administrative 
data not collected for research purposes. The Australian Institute of Health and Welfare 
undertook a validation study amongst the Australian general population and concluded that 
in the absence of an acute coronary heart disease event register, despite the limitations of 
using data linkage, it remains the best approach for estimating incidence rates43.  We had 
only summary level data for the general population and in calculating rates, assumed that 
the point prevalence population of Australia was at risk of IHD for the entire year.  This may 
have over-estimated actual time at risk and would bias estimates of IHD risk amongst the 
general population to being smaller than they actually are, though this is a limitation 
common to all studies using population data.   Our study only standardised rates by age, sex 
and year.  Data on rates by co-morbidities among the general population were not available 
to us, for example we did not have smoking status for the general population admissions and 
smoking is obviously a significant risk factor for IHD.  Recent Australian data from  2011-12 
showed that 53.5%  of over 18 year olds in the general population had never smoked, which 
was similar to those  treated for ESKD44.    
 
The findings from this study raise a number of important issues regarding the increased risk 
of cardiovascular disease in the ESKD population.  This population has double the risk of IHD 
events irrespective of our current preventative strategies suggesting a need for revision of 
both evaluation and treatment strategies in this high risk population. 
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TABLE 5.1   CHARACTERISTICS OF PARTICIPANTS WITH END-STAGE KIDNEY 
DISEASE, STRATIFIED BY HOSPITALISATIONS FOR IHD 
Characteristic Admission with 
 
No admission with  
 
All 
  N % N % N 
 Total, % 1961 18.2 8805 81.8 10766 
 Age at start of study (years)      
  <40  92 4.7 1632 18.5 1724 
  40<50 250 12.7 1238 14.1 1488 
  50<60 482 24.6 1580 17.9 2062 
  60<70 539 27.5 1873 21.3 2412 
  70<80 504 25.7 1971 22.4 2475 
  ≥80 94 4.8 511 5.8 605 
 Sex      
  Male 1251 63.8 5020 57.0 6271 
  Female 710 36.2 3785 43.0 4495 
 Racial background      
  White 1631 83.2 7271 82.6 8902 
  Asian 163 8.3 813 9.2 976 
  Other 186 9.5 702 8.0 888 
 Comorbidities at end-stage 
  
     
  Cerebrovascular disease  386 19.7 1260 14.3 1646 
  Diabetes  790 40.3 2550 29.0 3340 
  Coronary artery disease 1031 52.6 2753 31.3 3784 
  Peripheral vascular disease 622 31.7 1899 21.6 2521 
 Smoking status at end-stage 
  
     
  Never 906 46.2 4920 55.9 5826 
  Former or current 1055 53.8 3885 44.1 4940 
 Cause of kidney failure      
  Diabetes 597 30.4 1869 21.2 2466 
  Hypertension/renal artery 
 
305 15.6 1057 12.0 1362 
  Glomerulonephritis/IgA 
 
507 25.9 2794 31.7 3301 
  Polycystic kidney disease 135 6.9 697 8.2 832 
  Other 436 22.2 2369 26.9 2805 
 First renal replacement 
   
     
  Haemodialysis 1446 73.7 5987 68.0 7433 
  Peritoneal dialysis 523 26.7 2529 28.7 3052 
  Transplant 14 0.7 267 3.0 281 
 Transplanted during study 198 10.1 1712 19.4 1910 
 Died during study 1098 56.0 3442 39.1 4540 
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TABLE 5.2.  STANDARDISED INCIDENCE RATE RATIOS FOR HOSPITALISATION WITH IHD EVENTS IN PEOPLE WITH END-STAGE KIDNEY 
  DISEASE, BY AGE AND SEX 
*Observed, ‡ Expected, †Incidence rate ratio
Age at event (years) 
30-49 50-69 70-84 ≥85 
O* E‡ IRR† (95%CI) O* E‡ IRR† (95%CI) O* E‡ IRR† (95%CI) O* E‡ IRR† (95%CI) 
Male             
 Any IHD event 171 43.5 3.9(3.4, 4.6) 642 326.8 2.0 (1.8, 2.1) 411 318.3 1.3 (1.2, 1.4) 24 12.4 1.9 (1.3, 2.9) 
 Angina 80 20.4 3.9(3.2, 4.9) 297 169.6 1.8 (1.6, 2.0) 195 166.0 1.2 (1.0, 1.4) 5 5.9 0.8 (0.4, 2.0) 
 Acute MI 71 17.1 4.2 (3.3, 5.3) 294 98.9 3.0 (2.7, 3.3) 248 97.2 2.6 (2.3, 2.9) 19 6.6 2.9 (1.8, 4.5) 
 Chronic IHD  73 7.9 9.2 (7.3, 11.6) 253 92.5 2.7 (2.4, 3.1) 109 82.8 1.3 (1.1, 1.6) 3 1.5 2.1 (0.7, 6.4) 
              
Female             
 Any IHD event 71 7.3 9.8 (7.7, 12.3) 349 78.4 4.5 (4.0, 4.9) 273 120.3 2.3 (2.0, 2.6) 13 5.2 2.5 (1.5, 4.3) 
 Angina 40 4.4 9.2 (6.8, 12.5) 172 46.2 3.7 (3.2, 4.3) 126 67.5 1.9 (1.6, 2.2) 7 2.4 2.9 (1.4, 6.1) 
 Acute MI 27 2.1 13.0 (8.9, 18.9) 148 19.4 7.6 (6.5, 9.0) 168 37.0 4.5 (3.9, 5.3) 10 2.8 3.6 (1.9, 6.6) 
 Chronic IHD 28 1.0 27.4 (18.9, 39.6) 123 17.7 6.9 (5.8, 8.3) 46 24.4 1.9 (1.4, 2.5) 0 0.4 - 
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6.1 Abstract  
Background: Cardiac disease affects over two-thirds of patients with end-stage kidney 
disease (ESKD) and is the leading cause of death in this population.  Cardiac death rates 
have fallen in the general population, but benefits from improved preventative therapies 
and treatment of cardiac events may not be generalisable to people with ESKD.  We aimed 
to review absolute and relative rates for cardiac death in the ESKD population compared 
to the general population. 
Methods: Cohort study of incident people with ESKD in Australia and New Zealand, 1980-
2013.  Australian and New Zealand death registers were linked to Australian and New 
Zealand dialysis and transplant registry (ANZDATA) data to obtain date and cause of 
death. We calculated mortality rates for cardiac disease as defined by ICD-10-AM codes 
and standardised mortality ratios (SMR) compared with the general population using 
indirect standardisation, adjusting for age, sex, calendar year, and country. 
Results: We included 60,823 participants observed over 381,874 person-years, of whom 
34,322 died.  A primary cardiac death was recorded in 6847 participants (20%) and 27,475 
(80%) participants died of other causes.  Absolute cardiac death rates in the ESKD 
population were higher for men than women (men: 2002, 95%CI: 1945-2062; and 
women:1502, 95%CI:1444-1564/100,000 person-years) and both decreased over time.  
Relative to the general population, men and women with ESKD experienced more deaths 
(SMR in men: 5.6, 95%CI:5.5-5.8; and women: 8.3, 95%CI:8.0-8.6).  Excess deaths were 
greatest in younger ESKD patients, particularly women; aged 30-49 years women had 60 
times (SMR 60.0, 95%CI:51.8-69.0) whereas men had 18 times (SMR 17.7, 95%CI:15.9-
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19.7) more deaths than expected.  However, among people with ESKD cardiac death rates 
improved over time more markedly than for the general population, especially in women.  
Conclusions: Cardiac deaths in the Australian and New Zealand ESKD population are 
higher than expected in the general population, particularly at younger ages and women.  
Young women with ESKD have an excess relative risk of dying from cardiac causes, though 
there has been some improvement over time.  Disaggregation of these data by sex 
identifies differences which need to be addressed in future research. 
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6.2 Introduction 
Cardiac disease affects over two thirds of people with end stage kidney disease 
(ESKD)1.  The most prevalent cardiac diseases in ESKD include acute myocardial 
infarction (AMI), coronary artery disease (CAD), heart failure (HF), and sudden 
death/cardiac arrhythmias1. Cardiac disease is also the leading cause of death in the 
ESKD population with arrhythmia and cardiac arrests comprising 40% of known causes 
of death among dialysis patients, and 17% of the known causes of death among 
transplant recipients 1. 
 
In the general population, the age-standardised cardiac death rate has fallen over the 
past two decades with the largest decline occurring between 2000 and 2005 in both 
men and women2. Nearly half of this decrease has been attributed to improved 
application of treatments including primary and secondary preventative therapies3.  
Prevalence of risk factors has also changed, including decreases in smoking rates and 
increases in the treatment of hypertension3.   
 
The pathophysiology of cardiac disease is different in people with ESKD compared to 
the general population.  Accepted risk factors such as diabetes and hypertension are 
more prevalent 4 and act synergistically with ESKD to increase the risk of cardiac 
disease5.  Unique cardiovascular risk factors specifically associated with ESKD include 
albuminuria 6, uraemic toxins, fluid and electrolyte imbalance, and renal replacement 
itself.  These risk factors collectively contribute to oxidative stress, inflammation, 
immune dysfunction and disorders of bone and mineral metabolism leading to 
increased vascular calcification 7-10.   Primary preventative strategies for cardiovascular 
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disease used in the general population have little evidence of efficacy in the ESKD 
population 11-13 and studies have also shown that patients with ESKD are potentially 
under-investigated and under-treated for cardiac presentations, despite their 
increased risk 14.  It remains unclear whether improvements in cardiac mortality seen 
in the general population have also been evident in the ESKD population.   
Our study aimed to investigate comparative mortality over time, specifically cardiac 
mortality and sex differences, comparing people with ESKD to the Australian and New 
Zealand general population. 
 
6.3 Methods 
Study design and populations 
We performed a two nation cohort study of all adults starting treatment for ESKD in 
Australia and New Zealand from 1980 to 2013.   
 
We used the ANZDATA registry which has been described in detail elsewhere15. 
ANZDATA collects real time and annual survey data on all people undergoing 
treatment for ESKD from all centres in Australia and New Zealand.  These data include 
patient demographics, comorbidities, cause of ESKD and treatment-related 
information as well as the event of death and underlying mode of death.  Unlike 
international classification coding, the death is recorded by the treating nephrologist 
using 84 death codes, designed specifically for the registry to encompass common 
causes of death among people with ESKD excluding kidney disease and diabetes.  
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Both Australia and New Zealand operate mandatory death and cause of death 
reporting, with data aggregated in death registers, using internationally standardised 
coding to permit comparisons within and across populations. The Australian Institute 
for Health and Welfare (AIHW) collates death notifications and cause of death from 
the Registrars of Births, Deaths and Marriages in each state and territory.  The AIHW 
records the causes of death using the International Statistical Classification of Diseases 
and Related Health Problems tenth revision, Australian Modification (ICD-10-AM). The 
New Zealand Health Ministry uses data from The Mortality Collection (MORT) which 
classifies the underlying cause of death for all deaths registered in New Zealand also 
using the ICD-10-AMIn both countries, primary and contributory causes of death are 
recorded.  The primary cause of death is determined as the condition or event that 
initiated the sequence of events that led to the death.  Secondary or contributory 
causes of death are deemed to have contributed to death but did not initiate death.  
Data linkage of ANZDATA to these national death registers was undertaken to 
ascertain the date and cause of death in all people with ESKD in Australia and New 
Zealand. Linkage was performed for Australian participants by the AIHW using 
probabilistic linkage matching on identifiers including age, sex and name. The New 
Zealand Ministry of Health used deterministic linkage matching New Zealander 
participants on the National Health Index number. Best-practice privacy-preserving 
protocols were employed, where only de-identified data was made available to 
researchers after data linkage was performed. Ethics approval was granted by the 
University of Sydney (Project No.: 2014/917), AIHW (Reference No.: EO2015/3/181) 
and the New Zealand Ministry of Health (Reference No.: 14/NTB/171).  
 
 Chapter 6: Cardiac mortality in ESKD 
128 
 
Data on deaths in the general population were obtained from the Australian Bureau of 
Statistics for Australia and from the New Zealand Ministry of Health for New Zealand. 
Cause-specific (as recorded by ICD-10-AM) summary-level data on the number of 
deaths by sex, age (5-year age band) and calendar year, were obtained for each 
country, along with census data for the total population in each of these groups. Death 
register data were only available in Australia during 1980-2013 and in New Zealand 
during 1988-2012. Hence, our data linkage was limited by availability of general 
population data.  
 
Statistical methods  
The primary outcome was cardiac death. Cardiac deaths were identified from the 
underlying cause of death including ICD-10-AM codes: I20-I25, I34-I37 and I42-I50, 
listed in full in the supplementary material (Appendix 3, Table 1).  Subgroup analysis 
was performed for a priori groups of common cardiac diseases “Ischaemic heart 
disease (IHD) deaths” (I20-25), “valvular deaths” (I34-I37), “cardiomyopathy deaths” 
(I42), “arrhythmic deaths” (I44-49) and “heart failure deaths” (I50).  In supplementary 
analyses, we examined contributing causes of death among people with ESKD whose 
underlying cause of death was attributed to kidney disease in the Death Register 
(including diabetes E10-E14, kidney failure N17-N19, hypertensive disease I10-I15, 
glomerular disease N00-N08, other kidney or ureter disorders N25-N29 and renal 
tubule-interstitial disease N10-N16).  
 
Time at risk was measured from date of first treatment for ESKD, until death, or 31st 
December 2013 (AU) and 31st December 2012 (NZ), whichever came first.  Mortality 
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rates were calculated by age, sex, calendar year, and country for the ESKD population 
for each cardiac event type. Using all-cause and cause-specific cardiac mortality rates 
in the Australia and New Zealand general population, we used indirect standardisation 
to calculate standardised mortality ratios (SMRs) adjusting for country, age, sex and 
calendar year.   To investigate differences in those who died a cardiac death from 
those who died of other causes we used the rank-sum test for data not normally 
distributed and Chi-squared tests to examine categorical data. Linear regression was 
used on the log-transformed SMR to compare change over time. 
 
6.4 Results 
There were 60,823 participants included in the study contributing 381,874 person-
years of observation during which 34,322 (56%) people died.  Of those that died, 6847 
participants (20%) suffered a cardiac death and 27,475 (80%) participants died of other 
causes.  Participant characteristics are described in Table 6.1.  In the full cohort, there 
were more men (59%) than women (41%), and the majority of participants were from 
Australia (85%). A greater proportion of men died from cardiac (65%) than from other 
causes (56%).  The median age at starting treatment for ESKD was significantly higher 
in those with a cardiac death (p<0.001, median 64 years [IQR 55 to 72] compared to 63 
years [IQR 53 to 72]).  The age at death was also significantly higher in those with a 
cardiac death (p≤0.001, median 69 years [IQR 61 to 76 years] compared to 68 years 
[IQR 53 to 72 years]). The majority of participants were white (81%). The most 
prevalent cause of ESKD in the whole cohort was diabetes (28%), and the proportion of 
diabetics was lower in those who died of cardiac causes (26%) compared to other 
causes (30%;).   The proportion of participants diagnosed with coronary artery disease 
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and hypertension at commencement ESKD treatment was higher among those who 
died of cardiac causes. There were no important differences between countries so 
estimates are presented for both together. 
 
The absolute cardiac death rate for women was 1502 (95% CI: 1444-1564)/100,000 
person-years and for men was higher at 2002 (95% CI: 1945-2062)/100,000 person-
years.  As expected, the death rate increased as participants aged (Figure 6.1A).   
In relative terms, women with ESKD had more deaths than expected in the general 
population (SMR 8.3, 95% CI: 8.0-8.6) and had a greater excess mortality compared to 
men with ESKD (SMR 5.6, 95% CI: 5.5-5.8) (Figure 6.1B).  This difference was 
exaggerated in younger age groups but particularly in women. Among those aged 30-
49 years, women had 60 times (SMR 60.0, 95% CI: 51.8-69.0) more deaths than 
expected, while deaths in men had nearly 18 times more deaths than expected (SMR 
17.7, 95% CI: 15.9-19.7). 
 
Subgroup analysis of cardiac deaths revealed that IHD deaths represented the largest 
proportion of all cardiac deaths and similarly, relative to the general population, 
women had greater mortality compared to men (SMR in women: 9.0, 95% CI: 8.6-9.4; 
and in men 5.8, 95% CI: 5.6-6.0) (Figure 6.2).  This was substantially higher in the 
younger age group (30 to 49 years), nearing 70 times higher than the general 
population for women (SMR 68.5, 95%CI 58.7 to 79.9). There were fewer deaths in the 
other cardiac subgroups (Table 6.2), though SMRs remained high as ESKD patients still 
experienced an excess of cardiac deaths compared to the general population.  
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Cardiac death rates have been reducing over time and at a similar rate in both men 
and women (Figure 6.3).  Over the study period the SMR of cardiac deaths for women 
has significantly decreased over time (p-value<0.001), with the SMR halving from 13.4 
(95%CI 11.8 to 15.2) in 1980-1990 to 5.6 (95%CI 5.1 to 6.2) in 2010-2013. The 
reduction was much smaller in men and not statistically significant (P for trend 0.13), 
falling from 5.9 (95% CI 5.3 to 6.5) to 4.8 (95% CI 4.5 to 5.1) over the same period. 
 
An additional 7,738 participants died with a cardiac cause listed in at least one of the 
additional contributory causes.  Further breakdown of contributory causes revealed, 
ischaemic heart disease as a contributory cause of death in 6,090 participants; 
arrhythmia in 4187 participants and heart failure in 1866 participants.  The most 
prevalent primary causes of death in those with a cardiac contributory cause were 
diabetes (28%) and kidney failure (22%) (Appendix 3, Table 2). Of these 7,738 
participants, 4,431 (57%) had a primary cause of death related to their kidney disease.  
 
6.5 Discussion 
This large bi-national cohort study which examined the causes of death in people with 
ESKD over more than 30 years has three major novel findings.  First, there is significant 
disparity between the relative rates of cardiac death between women and men with 
ESKD and the general population.  Second, the burden of excess deaths in people with 
ESKD is most notable in the younger age groups. Third, over time there have been 
improvements in both the absolute and relative rates of cardiac deaths in the ESKD 
population and this improvement has been most notable in women with ESKD.  
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Our first major finding of sex disparity in the relative risk of cardiac death between 
men and   women with ESKD may potentially be explained by differences in coronary 
microvascular dysfunction. Most women with acute coronary syndromes have 
coronary atherosclerosis, but there are differences in the symptoms, presentation, 
pathology and the pathophysiology of coronary artery disease by sex 16,17.  Studies 
have also shown that women in the general population have higher mortality than 
men post intervention for myocardial infarction, evident in studies following both 
primary coronary angioplasty and coronary artery bypass grafting 18-22. One hypothesis 
is that in a high proportion of women, coronary microvascular dysfunction plays more 
of a role than coronary artery disease in the development of symptoms and cardiac 
mortality 23,24. The sex disparity is particularly apparent in the younger age groups and 
coronary microvascular dysfunction is facilitated by the loss of protective oestrogen 
cycling which occurs early in CKD.  Women on dialysis become menopausal 
significantly earlier than the general population and it is accepted that earlier age at 
menopause increases cardiovascular risk 25-27.  Ovarian dysfunction likely occurs early 
in CKD and progresses with CKD, largely through disruption of the normal 
hypothalamus–pituitary–gonadal axis28.  Oestrogen mediates its cardioprotective 
effect by increasing angiogenesis and vasodilation and decreasing reactive oxygen 
species, oxidative stress, and fibrosis, thus limiting cardiac remodelling 29.   There is 
also some evidence to suggest that oestrogen may help to protect cardiac endothelium 
from the adverse effects of uraemic toxins which may explain why the absolute cardiac 
mortality rates in women are still lower than in men with ESKD 30.  Potentially female 
sex (mediated by hormonal differences) and uraemic toxins have an additive or 
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synergistic effect on the microcirculation resulting in the vastly increased SMR for 
women.   
 
Our study describes the magnitude of excess cardiac deaths suffered by younger age 
groups with ESKD, as previously mentioned, most notable in young females. Reduced 
coronary flow reserve, a marker of coronary microvascular dysfunction is reduced in 
chronic kidney disease and may play a role in the pathogenesis of uremic cardiac 
disease 31.  The mechanisms of coronary microvascular dysfunction in CKD are not fully 
understood but it is likely that changes to the microvasculature begin early in CKD and 
are progressive causing ischaemia, fibrosis, remodelling and myocardial dysfunction32.   
These changes can occur independent of age and may explain the excess of deaths in 
the younger age groups.  Interestingly, there is increasing evidence that SGLT2 
inhibition can improve coronary microvascular dysfunction and this may be one of the 
drivers for the reduction in major cardiovascular events in the recent CREDENCE trial in 
patients with diabetes and CKD 33,34, though results were not stratified by sex.   
 
Last, we found evidence of decreasing cardiac mortality over time, particularly among 
women with ESKD.  Our previous work suggested that incidence rate ratios for cardiac 
events had improved over time for men but there had not been much improvement in 
women35.  These new data suggest that despite potentially no improvement in the 
prevention of cardiac events there has been improvement in the treatment of those 
events resulting in reduced death rates over time. The high relative risk in young ESKD 
patients is of particular interest and adds to the findings of a recent study in the USA 
which found high cardiovascular mortality rates in children and young adults with 
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ESKD.  However,  as this study did not use linked data they were unable to make 
unbiased comparison to the general population 36.  Our study also shows that these 
high mortality rates found in children remain a problem into adulthood and the excess 
of deaths in adults with ESKD may not be solely explained by the differences in causes 
of ESKD and the higher rates of comorbidity.   
 
The main strength of this study is that it is a large cohort encompassing the entire 
population of people with ESKD in Australia and New Zealand, which increases the 
generalisability of our results. The use of linked data allows the least biased 
comparison to the general population as deaths in both populations are ascertained in 
the same way. Further, it provides a long follow-up period and minimal to no biases 
due to loss to follow-up. There are some limitations inherent with the use of ICD 
coding including accuracy of the original diagnosis, medical record and the allocation 
of the code37. However, the ICD coding system is standardised internationally and 
therefore provides the least biased population comparisons.  The reported SMRs may 
be an underestimation in view of the potential additional cardiac deaths suggested by 
the contributory causes of death. It is likely that significant ascertainment bias exists in 
the coding of deaths in the ESKD population. A large proportion of primary causes of 
death were recorded as kidney failure and not a specific mechanism of death.  
 
This study highlights the excess risk of cardiac mortality within the ESKD population 
and in particular in young women.  The US National Institutes of Health has prioritised 
sex as a biological variable within research and this study contributes to our 
understanding of the interaction between sex and ESKD as major contributors to 
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cardiovascular mortality. Improvements have been made over time and our future 
work will look at risk factors as well as the impact of transplant on these risks. There 
remains a significant excess of risk for people with ESKD and by understanding the 
gender and age disparities we can generate tailored research hypotheses to address 
these risks.  
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6.7 Figures and tables 
FIGURE 6.1 (A)INCIDENCE RATES, AND (B) STANDARDISED MORTALITY RATIOS 
(SMR)* FOR ALL-CAUSE CARDIAC DEATHS IN THE AUSTRALIAN AND 
NEW ZEALAND ESKD POPULATION (1980-2013), BY AGE AND SEX. 
 
*SMRs are presented on a log scale 
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FIGURE 6.2 STANDARDISED MORTALITY RATIOS (SMR)* FOR SUBTYPES OF 
CARDIAC DEATHS IN THE AUSTRALIAN AND NEW ZEALAND ESKD 
POPULATION (1980-2013), BY AGE AND SEX.  
 
 
 *SMRs are presented on a log scale 
  
 Chapter 6: Cardiac mortality in ESKD 
142 
 
FIGURE 6.3 (A) INCIDENCE RATES AND (B) STANDARDISED MORTALITY RATIOS 
(SMR) FOR CARDIAC DEATH IN THE AUSTRALIAN AND NEW ZEALAND 
ESKD POPULATION, BY CALENDAR YEAR. 
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TABLE 6.1 CHARACTERISTICS OF ALL PATIENTS WITH END-STAGE KIDNEY DISEASE 
INCLUDED IN THE STUDY, STRATIFIED BY DEATH STATUS. 
 
Characteristics 
All cardiac deaths Other deaths Alive Total 
n (%) n (%)1 n (%) n (%)1 
Total, (%) 6843 (11)1 27,475 (45)2 26,505 (43)1 60,823 (100) 
Age at commencement of RRT (years)        
 Median [IQR] 64 [55,72] 63 [53,72] 52 [38,64] 59 [46,70] 
Age at death (years)         
 Median [IQR] 69 [61, 76] 68 [58,76]     
Gender         
     Female 2404 (35) 11,969 (44) 10,669 (40) 25,042 (41) 
     Male 4439 (65) 15,506 (56) 15,836 (60) 35,781 (59) 
Year of commencing ESKD         
 ≤1990 1,413 (21) 5,065 (18) 1,770 (7) 8,248 (14) 
 1991-1999 2226 (33) 8,708 (32) 3,819 (14) 14,753 (24) 
 2000-2009 2876 (42) 12,067 (44) 11,401 (43) 26,344 (43) 
 2010-2013 328 (5) 1635 (6) 9,515 (36) 11,478 (19) 
Country         
 Australia 5795 (85) 23,197 (84) 22,459 (85) 51,451 (85) 
 New Zealand 1048 (15) 4278 (16) 4,046 (15) 9,372 (15) 
Racial background         
 Caucasian 5523 (81) 21,504 (78) 19,003 (72) 46,030 (76) 
 Asian 270 (4) 1307 (5) 2304 (9) 3881 (6) 
 Australian first nations* 402 (6) 1941 (7) 1905 (7) 4248 (7) 
 People of  the PI & Maori 582 (9) 2412 (9) 2407 (9) 5401 (9) 
 Other 66 (1) 311 (1) 886 (3) 1263 (2) 
Comorbidities at ESKD         
 Cerebrovascular disease 1170 (17) 4469 (16) 2,037 (8) 7,676 (13) 
 Diabetes 2390 (35) 10,786 (39) 8,541 (32) 21,717 (36) 
 Coronary artery disease 3626 (53) 11,056 (40) 6,103 (23) 20,785 (34) 
 Hypertension 3454 (50) 13,273 (48) 7238 (27) 23,965 (39) 
 Previous malignancy 1447 (17) 8,468 (31) 5,873 (22) 15,788 (26) 
Smoking status         
 Current/Former 3429 (50) 13,065 (48) 11,895 (45) 28,389 (47) 
 Never 2163 (8) 10,137 (37) 13,561 (51) 25,861 (43) 
 Not recorded 1251 (<0.5) 4,273 (16) 1,049 (4) 6,573 (11) 
Cause of renal failure         
 Diabetes 1805 (26) 8357 (30) 6,735 (25) 16,909 (28) 
 Hypertension/RA disease 1460 (21) 3472 (13) 2,332 (9) 7,264 (12) 
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 GN/IgA nephropathy 1547 (23) 6290 (23) 8,795 (33) 16,632 (27) 
 Polycystic kidney disease 314 (5) 1440 (5) 2,491 (9) 4,245 (7) 
 Analgesic nephropathy 528 (8) 1971 (7) 385 (1) 2884 (5) 
 Unknown diagnosis 539 (8) 1850 (7) 1223 (5) 3612 (6) 
 Other 646 (9) 4077 (15) 4441 (17) 9164 (15) 
Transplanted at beginning of study 16 (<0.5) 139 (<0.5) 1,494 (0.1) 1,649 (3) 
Transplanted during study 920 (13) 4,231 (15) 11,051 (42) 16,202 (27) 
12Column percentage 3 Aboriginal and Torres Strait Islands, RRT = Renal replacement 
therapy, ESKD= end stage kidney disease, RA=renal artery , GN= glomerulonephritis,. 
PI=Pacific Islands 
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CHAPTER 7   
COGNITION IN PEOPLE WITH END-STAGE KIDNEY DISEASE 
TREATED WITH HAEMODIALYSIS: A SYSTEMATIC REVIEW 
AND META-ANALYSIS 
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7.1 Abstract 
Background: Cognitive impairment is associated with poorer quality of life, risk of 
hospitalisation and mortality.  Cognitive impairment is common in people with end-stage 
kidney disease treated with haemodialysis, yet the severity and specific cognitive deficits 
uncertain. 
Study Design: Systematic review and meta-analysis. 
Setting & Population: Adults on haemodialysis compared with the general population, 
people on peritoneal dialysis or with chronic or nondialyzed chronic kidney failure. 
Selection criteria for studies: Randomised control trials, cohort or cross sectional studies 
without language restriction.    
Index tests: Validated neuropsychological tests of cognition 
Outcomes: Cognitive test scores, aggregated by cognitive domain: orientation and 
attention, perception, memory, language, construction and motor performance, concept 
formation and reasoning, and executive functions. 
Results: 42 studies of 3522 participants.  Studies were of high or uncertain risk of bias, 
assessed by the Newcastle-Ottawa scale.   People treated with haemodialysis had worse 
cognition than the general population, particularly in attention (N=22 standardised mean 
difference, SMD, -0.93, 95% CI -1.18, -0.68). Haemodialysis patients performed better than 
nondialyzed chronic kidney failure in attention (N=6 SMD 0.70, CI 0.45, 0.96) and memory 
(N=6 SMD 0.36 CI 0.08, 0.63) but had poorer memory than the general population (N=16 
SMD -0.41 CI -0.91, 0.09) and people with CKD (N=5 SMD -0.40, CI -0.60, -0.21). There was 
insufficient data to show other differences among people on haemodialysis and people on 
PD or with CKD. 
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Limitations: Potentially biased studies, not wholly adjusted for education.  High 
heterogeneity, mainly due to the large variety of tests used to assess cognition. 
Conclusions:  People treated with haemodialysis have impaired cognitive function 
compared to the general population, particularly in the domains of orientation and 
attention and executive function. Cognitive deficits in specific domains should be further 
explored in this population and be considered when approaching education and chronic 
disease management.   
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7.2 Introduction 
Cognitive impairment is the deterioration in cognitive function beyond that which might be 
expected from normal ageing and is usually chronic and progressive1,2.  Cognition describes 
several discrete skill domains and these may be differently affected by pathophysiological 
mechanisms. ‘Normal’ ageing is associated with decline in executive function and memory 
(episodic and working) 3, 4.  Dialysis patients have many of the known risk factors for 
cognitive impairment including; hypertension, diabetes and dyslipidaemia5-7.  In addition, 
dialysis patients are exposed to hypoxaemia, large fluid and osmolar shifts, fluctuating titres 
of uraemic toxins and a pro-inflammatory state, all factors purported to affect cognitive 
function8-10.   
 
Chronic kidney disease (CKD) is associated with an increased risk of cognitive impairment11. 
Up to 70% of haemodialysis patients aged 55 years and older have moderate to severe 
cognitive impairment, which is up to three times higher than age-matched controls12-14.  The 
specific domains of cognition most affected in people on dialysis remain unclear. 
Cognitive impairment contributes significantly to the burden of disease and disability in the 
community and as such has been made a national health priority in several countries15,16.  
Cognitive skills are needed to access health services, process, understand and recall written 
and spoken information and assimilate and express decisions about health care17.  Impaired 
cognition has been linked to reduced health literacy, decreased medication adherence, 
impaired physical and mental health and a greater risk of death18-22.  This is of particular 
relevance to dialysis patients as they access health services almost more than any other 
population23,24.   
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Most studies of cognition in people treated with haemodialysis have been of relatively small 
size and few have sought to establish how cognition varies between people treated with 
haemodialysis compared to: people with no kidney disease (general population), CKD, 
people on peritoneal dialysis (PD), and people with nondialyzed chronic kidney failure 
(nondialyzed CKF). 
 
7.3 Methods 
Protocol  
The study protocol was registered with the International Prospective Register of Systematic 
Reviews (PROSPERO, CRD4201401522625).  This work is reported according to Meta-analysis 
Of Observational Studies in Epidemiology (MOOSE) criteria. 
  
Eligibility criteria and search strategies 
We included all randomised controlled trials, cohort and cross-sectional studies reporting 
cognitive function among people with end-stage kidney disease treated with haemodialysis 
compared to other specified populations (general population, people with CKD, people on 
PD and people with nondialyzed CKF). There was no language restriction. Studies must have 
used a validated measure of cognitive function.  We excluded studies in children (<18 years).   
We searched MEDLINE, EMBASE and CENTRAL (inception to 30th June 2015) using a sensitive 
search strategy developed by a specialist librarian (Appendix 4 Table 1).  
 
Study selection, data collection and risk of bias appraisal 
Two reviewers (of PM, SW, EO, MC) independently screened titles and abstracts of retrieved 
citations and where necessary, full text, to identify potentially eligible studies.    
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Two reviewers (EO, MC) independently abstracted pre-specified data including test scores 
from neuropsychological tests of cognition, using a standardised data extraction form. 
Disagreements were resolved on discussion with a third investigator (ACW).  Where more 
than one publication of a study existed, reports were grouped and all relevant outcome data 
included. When repeated measures were collected on individuals within studies we 
prioritized the measure taken 24 hours following dialysis.   Study and participant 
characteristics were collated. 
 
We assessed study risk of bias using the Newcastle-Ottawa scale for cohort or cross-
sectional study designs 26. The Newcastle-Ottawa scale is a tool to assess potential bias in 
studies and each study is awarded stars for eight bias reducing measures: selection of the 
study groups (maximum four stars for cohort and five stars for cross-sectional studies); 
comparability of the groups (maximum two stars); ascertainment of outcome of interest for 
case-control or cohort studies (maximum 3 stars).  The selection measures were awarded 
stars based on representative samples and sample size.  We judged age, previous 
cerebrovascular disease and diabetes mellitus as the most important potential confounders 
and scored comparability as: one star awarded if age was adjusted for and two stars if age 
and either cerebrovascular disease or diabetes mellitus were adjusted for.  For outcome 
assessment, we awarded two stars if outcome assessors were blinded to whether 
participants were on dialysis, and one further star for presentation of statistical data (p 
value or 95% CI).  
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Summary measures and synthesis of results 
The many available tests of cognition vary in the particular domains they assess.  To 
examine patterns of cognitive deficit across studies, two clinical psychologists with expertise 
in cognition (DG, DP) independently mapped each cognitive test to the cognitive skill it best 
measured. We classified cognitive domains using a commonly used neuropsychiatric 
framework:  orientation and attention (primarily tests of attention, sustained attention, 
concentration, and processing speed), perception, memory, verbal functions and language, 
construction and motor performance, concept formation and reasoning, and executive 
functions 27.    Tests which could not be assigned to one primary cognitive domain (including 
IQ and general cognitive screening tests) were classified as assessing global cognition.  
Mapping agreement between the two psychologists was assessed using the kappa statistic.   
 
In order to combine different tests and measurement scales within each domain, we used 
standardised mean differences (SMD and 95% confidence interval [CI]). We aligned scales by 
multiplying mean values from tests where a higher score indicated a poorer cognitive test 
score, by -1.  Where studies administered several different tests assessing the same 
cognitive domain, we synthesized overall scores by domain by computing a combined effect 
size and variance of that mean using a correlation coefficient of 0.5.   We undertook 
sensitivity analysis using correlation coefficients of 0.01, 0.1 and 0.9. 28.  Meta-analysis was 
performed, as per Cochrane methodology, using a random-effects model, with 
heterogeneity investigated using Chi2 on N-1 degrees of freedom, with an alpha of 0.05 used 
to represent evidence of statistical significance.  We analysed the data using the profile-
likelihood random-effects method as a sensitivity analysis, no substantive differences were 
found (results available on request).  We assumed I2 test values from 0-40% represented 
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heterogeneity which might not be important, 30-60% represented moderate heterogeneity, 
50-90% represented substantial heterogeneity and 75-100% represented considerable 
heterogeneity 29.  
 
To demonstrate clinical applicability, we multiplied the summary SMD by the pooled 
standard deviation from the largest study, for the most frequent test within each domain. 
This allowed the summary effect to be re-expressed in terms of the original units of that 
instrument, to understand whether observed differences might be clinically important24. 
 
Subgroup and sensitivity analyses  
We did pre-specified subgroup analyses and meta-regression to explore potential sources of 
heterogeneity.  We examined whether differences in cognition were affected by study 
populations (differing definitions of CKD, nondialyzed CKF and selection of general 
population).  We examined year the study was conducted, comparing studies published 
after 1995 versus before 1995, as around this time there was widespread reduction in the 
use of aluminium in dialysate, a contributor to aluminium-related dementia.  To investigate 
the effect of potential bias we performed sensitivity analyses, using only data from studies 
that scored >4 out of a total of 9 stars in the Newcastle-Ottawa Scale. 
 
7.4 Results 
We identified 49 eligible studies involving 4964 participants (Figure 7.1).   We were unable 
to include data from 7 studies (1442 participants) as cognitive data were not dis-aggregated 
by population or test (Appendix 4 Table 2).   The remaining 42 studies consisted of 38 cross-
sectional and four cohort studies, described in Table 7.1.  Seventeen studies were 
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performed in the USA (40%), 14 studies in Europe (33%), six studies in Asia and the Middle 
East (14%), three studies in Central and South America (7%) and two studies in Africa (5%). 
Patient characteristics are described in Table 7.1.  The median number of participants in the 
studies was 57, range 20-490.  The mean age of all study participants was 51.4 years (SD 
10.6, range 32.0–69.5) and in tests of interaction there were no statistical differences 
(p>0.05) between the age of the haemodialysis population and any other population. The 
mean proportion of men was 63.1% (range 0-100%).  Race was only reported in 10 studies; 
on average 59.0% were white, 40.0% black, 20.5% Asian and 12.9% were reported as other. 
 
Risk of bias 
The four cohort studies achieved higher total scores (median 7 stars out of 9,range 5-9 stars) 
in the Newcastle-Ottawa scale than the 38 cross-sectional studies (median 4 stars out of 10, 
range 3-8 stars) (Figure 7.2).  Within the selection category very few studies reported 
sampling strategy, justified the sample size or described the non-respondents; the median 
number of stars obtained was two for cross-sectional studies but 3.5 for cohort studies.  In 
the comparability category; 38 (90.5%) studies adjusted for age though only 23 (54.8%) 
adjusted for education.  Only five studies (12%) adjusted for age and either diabetes mellitus 
or cerebrovascular disease (Table 7.1).  Sixteen studies excluded patients already diagnosed 
with dementia or those who had an MMSE <24.  Thirteen studies excluded those with a 
previous history of stroke.   In assessing outcome the assessor was only blinded to whether 
the patient was on haemodialysis in one study.  
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Cognitive Tests 
Inter-rater agreement (DP, DG) of the primary cognitive domain that each test assessed was 
excellent, with a kappa statistic of 0.95.  
  
Studies used multiple tests, often measuring the same domain numerous times.  Fifty four 
different cognitive tests were employed over the 42 studies. Within each study, a median of 
5 tests (range 1-41) were used.  Overall, global cognition was measured in 27 (64.3%) 
studies. Orientation and attention was the most frequently measured in 33 (78.6%) studies 
and perception the least frequently measured in only four (9.5%) studies (Figure 7.3).     
A large variety of tests were used to measure each cognitive domain, the most common test 
was the MMSE, used 25 times out of 49 measures of global cognition (53%).  The most 
frequent test used in the other domains varied from being used 17-37% of the time (Figure 
7.3).   
 
People on haemodialysis compared to the general population. 
The participants in the general population groups across the 32 studies were somewhat 
heterogeneous; they included healthy volunteers, people selected from outpatient clinics, 
relatives and friends of people on dialysis, living kidney donors and primary care patients. 
People on haemodialysis had significantly lower cognitive test scores than the general 
population in all domains apart from perception, where data were sparse and imprecise 
(Figure 7.4).  The SMD, number of studies and participants across each cognitive domain is 
shown in Appendix 4 Table 4.  People on haemodialysis performed most poorly compared to 
the general population in tests of orientation and attention (SMD -0.93, CIs -1.18, -0.68).  It 
is worth noting that the majority of tests assessing the domain of orientation and attention 
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focussed on attention, processing speed and working memory (this is the case for all of the 
following results where the domain of orientation and attention is referred to.)  
Global cognition was tested 23 times in 18 studies (583 haemodialysis and 562 general 
population participants), SMD -0.70 (CI -0.95 to -0.45). In absolute terms, this equates to 1.1 
point lower MMSE score in adults treated with haemodialysis compared to the general 
population (Figure 7.5). 
 
Orientation and attention was measured in 22 studies (969 haemodialysis and 722 people in 
the general population) SMD -0.93 (CI -1.18 to -0.68).  For this domain the most frequently 
performed test was the Trail-Making Test A (TMT-A), measured in 470 people on 
haemodialysis and 285 general population.  In absolute terms, this SMD suggested 
haemodialysis patients were 11.4 seconds slower than the general population in performing 
the TMT-A test (Figure 7.5). 
 
Tests of interaction to investigate  potential sources of heterogeneity did not reach 
statistical significance  ( p>0.09, details in Appendix 4 Table 3).We firstly restricted studies to 
those in which haemodialysis patients were compared with only healthy, age matched 
controls.  All domains showed a small increase in difference, but I2 did not change (Appendix 
4 Table 4).   Restricting to studies published since 1995, improved heterogeneity for memory 
(I2 56% to 35%) and construction and motor skills (I2 78% to 30%) (Appendix 4 Table 4).  
Including only studies with lower risk of bias (>4 stars out of 9 in the Newcastle-Ottawa 
scale) improved heterogeneity for memory (56% to 32% in 6 studies) and construction and 
motor (78% to 0% in 5 studies) (Appendix 4 Table 4).   
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People on haemodialysis compared to people with CKD. 
The majority of studies defined CKD as between Stages 2 and 4, one study included some 
acute kidney injury patients and two studies had ambiguous definitions including “pre-
dialysis”.  
 
People on haemodialysis had lower memory scores than people with CKD (Figure 7.4), 
tested nine times in five studies (221 haemodialysis and 201 CKD participants) SMD -0.40 
(CI-0.60 to -0.21).  In all other domains the differences were either not statistically 
significant or imprecise (Figure 7.4). 
 
To investigate heterogeneity we excluded studies where the patients with acute kidney 
injury or undefined “predialysis” groups were included, this did not affect the I2 value 
(Appendix 4 Table 5). Only one study was performed after 1995 and analysing only studies 
with low risk of bias did not explain heterogeneity (Appendix 4 Table 5).    
 
 People on haemodialysis compared to people on PD 
People on haemodialysis performed more poorly in tests of executive function than people 
on PD (Figure 7.4), tested four times in two studies (464 haemodialysis and 65 PD 
participants, I2 89%) SMD -0.98 (CI -1.91 to -0.05).  Both studies adjusted for age, diabetes 
and stroke though only one adjusted for education.  The results for language were based on 
one study (338 haemodialysis and 51 PD patients) where haemodialysis patients were 
poorer, SMD -0.31(CI -0.60 to -0.01).  In all other domains the mean difference did not meet 
significance (Figure 7.4). 
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The analyses excluding studies published before 1995 and those with a high risk of bias did 
not explain the high heterogeneity (Appendix 4 Table 6).  Other potential sources of 
between-study heterogeneity could not be explored due to insufficient observations.   
 
People on haemodialysis compared to people with nondialyzed CKF. 
The nondialyzed CKF comparator group included one study with conservative care patients, 
one “severe azotemia” population, two studies with people immediately prior to starting 
dialysis and three studies which quoted mean creatinine within the range of CKD stage 5. 
People on haemodialysis performed better than people with nondialyzed CKF in orientation 
and attention, measured 22 times in 6 studies, (128 haemodialysis and 73 nondialyzed CKF 
participants) SMD 0.70 (CI 0.45 to 0.96), and memory, measured 16 times in 6 studies (135 
haemodialysis and 81 nondialysed CKF participants) SMD 0.36 (CI 0.08 to 0.63) (Figure 7.4).   
 
In absolute terms nondialyzed CKF patients performed the TMT-A test, measuring 
orientation and attention, 12.3 seconds slower than people on haemodialysis (Figure 7.5). 
Removing studies which included conservative care patients and studies which only 
described the group as “severely azotemic” made little difference to either the magnitude of 
effect nor heterogeneity (Appendix 4 Table 1). 
 
7.5 Discussion 
We present a systematic summary of cognitive impairment in people on haemodialysis, and 
more specifically the patterns of cognitive domains most affected   People on haemodialysis 
demonstrated more cognitive impairment than the general population in most cognitive 
domains.  There were pronounced deficits in orientation and attention, memory and also 
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executive function.  There is not sufficient evidence to find any major differences between 
people on haemodialysis compared with either PD or those with CKD apart from a small 
decline in memory compared to people with CKD.  Finally, there is some limited evidence 
that people treated with haemodialysis may perform better in tests of attention and 
memory compared to those with nondialyzed CKF.  
 
In the process of normal aging the most affected domains are memory and executive 
functions3,30.  We found that in people on haemodialysis, memory and executive function 
are impaired but that the domain of orientation and attention is particularly compromised. 
This impairment was predominantly found in tests of attention, processing speed and 
working memory. Our findings, based on limited evidence, suggests that as people with 
nondialyzed CKF perform more poorly than people on dialysis in these tests, this deficit may 
be reversible to some degree.  There appears to be a spectrum of declining cognitive 
function from people in the general population through haemodialysis to those with 
nondialyzed CKF.   
 
This impairment in orientation and attention may have particular clinical implications. The 
LitCog study  found a strong correlation between orientation and attention (measured as 
processing speed) and several literacy measures including the Test of Functional Health 
Literacy in Adults  (r=0.68) 17,31.  Deficits in orientation and attention greatly affect an 
individuals’ ability to actively process information which has a significant association with 
poorer health literacy and poorer performance of common health tasks 17.  This is 
particularly important in a clinical setting because it is often peri-CKF and again whilst on 
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haemodialysis that people are counselled with regards to choice of renal replacement 
therapy, transplantation options and education in how that therapy is implemented.  
  
The prominence in the deficit in orientation and attention also suggests the possibility that 
there is a different pathophysiological pathway causing the deficits in cognitive function for 
people on haemodialysis, neither accelerated aging nor early vascular dementia.  In our own 
work, a systematic review looking at cognition in people with ESKD pre and post-transplant, 
we have shown that there is improvement, particularly in orientation and attention, 
memory, construction and motor performance after transplantation32.  This would suggest 
that the cognitive deficits in people on haemodialysis may be at least partially reversible and 
potentially metabolic in origin.  Whether any reversibility is dose dependent is not clear.   
 
The main strength of our study is that we comprehensively synthesised data and analysed 
by cognitive domain.  There is currently no gold standard cognitive test battery for CKD and 
we found multiple tests had been used both within and across studies. Our approach was to 
map every cognitive test reported, to the broad cognitive skill domain the test assessed (and 
achieved extremely close inter-rater agreement between two clinical psychologists based in 
different countries). We used a validated method for analysing correlated data to synthesize 
data from every cognitive test used on the same people within studies, thereby avoiding 
potential bias in selecting which data to include.    
 
Our synthesis had several limitations.  Many of the studies excluded people with MMSE <24 
or diagnosed with dementia from both the control and intervention groups.  This may 
introduce bias, and so underestimate the size of differences.  The average age of 
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participants in our study was 52.9 years and this is somewhat younger than the 
contemporary age in many developed populations33,34 but reflects practices worldwide.  The 
majority of studies adjusted for age, but education was only adjusted for in about half of the 
studies, which may also introduce bias. The lack of an agreed standard tool for measuring 
cognition in CKD has led to a multitude of tests being used and leaves our study open to the 
potential of outcome reporting bias.   Studies frequently presented crude (unadjusted) 
cognitive tests scores and did not report other potential confounders that might affect 
cognition in people on dialysis, for example; comorbid cardiovascular disease, stroke, and 
dialysis adequacy.  Our analyses were also subject to assumptions about correlations among 
different cognitive tests used at the same time.  We used conservative estimates of 
correlation from published reports but could not verify our assumptions without access to 
individual participant test score data or more detailed statistical reporting of study summary 
level data.  Other potential explanations for the heterogeneity include: inherent difficulties 
analysing continuous scales using SMD where statistical heterogeneity is inevitable35, the  
sparse data for many comparisons, the broad range of comparator groups and the high 
variability in the tests used to test each domain. The choice of the random-effects model 
acknowledged the a priori assumption of high heterogeneity.  Many of the studies included 
in this meta-analysis performed poorly on the Newcastle-Ottawa scale, suggesting low 
quality evidence.  It is difficult to ascertain how clinically relevant the demonstrated 
difference between measures of cognition in the haemodialysis population and the general 
population are.   
 
A strength of our work is that to try and account for this we expressed SMD in absolute 
terms. The MMSE difference of 1.1 point lower was statistically significant (p=<0.03), but it 
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is unclear whether this difference is clinically important in such a blunt tool.  Contrastingly, 
when we calculated absolute difference for orientation and attention, using the TMT-A test, 
the haemodialysis population were 11.4 seconds slower than the general population; we 
found that people on haemodialysis were classed as having extremely low performance 
relative to normative data for age 55-74 years. In our analysis set the general population 
were classified as low average (Figure 7.5); this was skewed by one study with exceptionally 
long test times, removal of this study resulted in the general population falling into the 
normative data “Average” category).27 This information emphasises the clinical applicability 
of our work.  
 
This study also highlights areas where improvements can be made in the design of future 
studies; principally reaching consensus on which cognitive tests should be used in the 
haemodialysis population to allow for meaningful comparison between studies and more 
detailed information on areas of impairment. A pragmatic way forward may be to 
incorporate testing for each cognitive domain into standardised reporting outcomes for 
haemodialysis. 
 
Cognitive impairment on dialysis impacts the individual patient journey as well as the public 
health agenda.  Understanding the specific domains affected in cognitive impairment on 
dialysis can help shape service delivery and patient self-management initiatives.   
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7.7 Figures and tables 
FIGURE 7.1 LITERATURE SEARCH  
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FIGURE 7.2 RISK OF BIAS(NEWCASTLE OTTAWA SCALE)* 
 
*Guide to allocation of stars: Selection:  Representation of sample: all subjects or random sampling or non random sampling*, no description or selected users – no stars  
    Sample size: Justified and satisfied*, no justification or no description  – no stars 
    Non-respondents: comparability established and response rate satisfactory*, unsatisfactory response rate or no description – no stars 
    Tool:  validated**    Comparability: Adjusted for age*, Adjusted for age and cerebrovascular disease OR diabetes** 
    Outcomes: Statistical test presented*,Outcome assessor blinded** 
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FIGURE 7.4 COGNITIVE SCORES STRATIFIED BY COGNITIVE DOMAINS  
 
 
HD = Haemodialysis, Gen pop = General population, PD = Peritoneal dialysis, ESKD = non dialysed end stage kidney disease  
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FIGURE 7.5 ESTIMATED DIFFERENCES IN COGNITIVE TESTS 
*Pezzotti P, Scalmana S, Mastromattei A, Di Lallo D, the "Progetto Alzheimer" Working Group. The accuracy of the MMSE in 
detecting cognitive impairment when administered by general practitioners: A prospective observational study. BMC Fam 
Pract. 2008; 9: 29 
†Normative data for ages 55-74 Ashendorf L, Jefferson AL, O’Connor MK, Chaisson C, Green RC, Stern RA. Trail Making Test 
Errors in Normal Aging, Mild Cognitive Impairment, and Dementia. Archives of clinical neuropsychology : the official journal 
of the National Academy of Neuropsychologists. 2008;23(2):129-137.  
 ‡ The mean time for our general population was skewed by one study and when this study was excluded the mean time 
fell into the “Average performance” category. 
HD = Haemodialysis, Gen pop = General population, PD = Peritoneal dialysis, Nd ESKD = non dialysed end stage kidney 
disease  
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TABLE 7.1 CHARACTERISTICS OF STUDIES INCLUDED IN META-ANALYSIS, STRATIFIED BY COMPARATOR GROUP 
Author Country Total (n) % Men 
Mean age 
(years) 
Mean HD duration 
(years) (SD/range) 
Risk of Bias 
      
Selection 
Max 4stars 
Comparison 
Max 2 stars 
Outcome 
Max 3 stars 
Haemodialysis versus General population 
    
   
Alexander 1980 USA 56 unknown unknown 
 
2 1 1 
Bae 2008 South Korea 27 59.1 48.8 3.3(3.2) 2 1 1 
Bossola 2011† Italy 240 60.0 67.0 4.9(4.9) 2 1 1 
Dahbour 2009† Jordan 108 73.4 46.7 8.5(5.9) 4 2 3 
Fazekas 1996 Austria 40 28.0 58.0 2.7 3 1 1 
Figueiredo 2007 Brasil 57 19.1 37.9 2.8(2.0) 2 1 1 
Grimm 1990 Austria 65 10.8 51.5 2.9(2.5) 2 0 1 
Harciarek 2009† Poland 50 66.0 46.4 4.7(4.0) 3 2 1 
Harciarek 2010 Poland 91 69.6 48.3 5.3(6.2) 4 2 2 
Kramer 1996† Austria 60 21.9 44.0 unknown 3 1 2 
Lux 2010 Germany 24 91.7 44.9 unknown 2 1 1 
Madan 2007 India 30 0.0 32.0 unknown 2 1 1 
Murray 2006 USA 202 50.5 69.5 3.0(3.5) 3 1 1 
Pliskin 1996 USA 28 32.1 59.3 3.2(0.5-7.0) 2 1 1 
Post 2012 USA 76 100.0 63.3 2.5(3.8) 3 1 1 
Shin 2013 USA 28 67.9 49.3 4.3(3.0) 2 1 1 
Umans 1998 USA 20 unknown 61.5 unknown 2 1 1 
      
   
Haemodialysis versus chronic kidney disease 
   
   
Kurella 2004 USA 160 64.4 62.7 3(1.7-4.0) 5 2 1 
Rabinowitz 1980 South Africa 34 unknown unknown unknown 2 0 1 
Post 2010 USA 51 100.0 67.2 unknown 3 2 1 
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Haemodialysis versus peritoneal dialysis 
    
   
Buoncristiani 1993 Italy 37 unknown 59.6 unknown 2 1 1 
Cukor 2013 USA 31 10.0 49.6 4.5(3.9) 2 1 1 
Griva 2003 UK 145 64.8 50.1 4.4(4.6) 4 1 1 
Radic 2011 Croatia 42 unknown 50.3 7.1(4.3) 2 1 1 
Sithinamsuwan 2005 Thailand 90 36.7 54.3 5.7(2.8) 2 1 1 
Williams 2004 USA 30 50.0 51.4 5.5(1.1) 2 0 1 
Wolcott 1988 USA 35 63.1 50.2 5.8(4.2) 2 1 1 
McKee 1982 USA 34 50.0 unknown unknown 2 0 1 
Takuma 1987 Japan 65 unknown unknown unknown 2 0 1 
      
   
Haemodialysis versus multiple comparator groups 
   
   
Caltagirone 1987 Italy 28 unknown 45.4 
 
2 1 1 
Conde 2010 Brasil 119 50.1 58.5 4.7(0.8) 2 1 1 
Garcia-Maldonado 1991 USA 56 100.0 53.5 3.4(0.6) 2 1 1 
Hart 1983 USA 62 62.9 41.1 2.7(2.7) 2 1 1 
Heidbreder 1979 Germany 98 49.0 45.0 unknown 2 1 1 
Kaliroa 2011 USA 490 53.2 69.2 2.7(2.7) 2 1 1 
Kato 2012 Japan 100 47.3 68.2 unknown 2 1 1 
Nasser 2012 Egypt 120 53.6 43 unknown 3 1 1 
Ryan 1981 USA 48 100.0 48.1 3.2(2.1) 2 1 1 
Sanchez-Roman 2011 Mexico 161 unknown 36.6 unknown 3 1 1 
Sujic 1997 Croatia 50 unknown unknown unknown 2 1 1 
Teschan 1979 USA 167 unknown 53.6 unknown 2 1 1 
Tilki 2004 Turkey 67 50.7 40.5 5.2 2 1 1 
*7 additional studies did not provide data suitable for synthesis (Appendix 4 Table 2), †Cohort study HD = Haemodialysis, GP = general 
population, CKD = chronic kidney disease, PD = peritoneal dialysis, ESKD = non dialysed end stage kidney disease. 
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The aims of this thesis were to examine CVD in the ESKD population by investigating 
priorities and outcomes. Firstly, to ascertain the priorities of patients and health 
professionals and to standardise them as outcome measures of CVD for use in trials in 
haemodialysis.  Secondly to identify patterns in the epidemiology and impact of CVD in 
the ESKD population 
 
I addressed my aims using both quantitative and qualitative methods.  I performed 
systematic reviews to describe the contemporary use of cardiovascular outcomes 
(Chapter 2) and to meta-analyse smaller trials assessing cognition in people with ESKD 
(Chapter 7).   I used two types of survey methods in terms of absolute (Likert scale) 
and relative (best-worst scaling) importance, which elicited stakeholder preferences 
about the most important measures of CVD to be used as core outcome measures 
(Chapter 3). I convened an international consensus workshop (Chapter 4), which 
provided considerations for establishing a CVD core outcome measure in terms of its 
relevance to haemodialysis, difficulties with defining outcomes and considerations for 
implementation.  I also employed thematic analysis to reflect comments from the 
survey and contributions from participants at the consensus workshop.  
 
I made efficient use of routinely collected clinical and administrative datasets and 
ensured minimal bias by using linked health data to make population-based 
comparisons. I used a wide range of epidemiological methods to describe patterns of 
CVD in ESKD, resulting in novel findings, such as discrepancies in outcomes for women 
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compared to men.  To facilitate simple clinical application I expressed the findings in 
terms of absolute risk and risk relative to the general population (Chapters 5 and 6).   
 
Implications of main findings 
 
Cardiovascular outcomes in trials of people on haemodialysis 
I have characterized the variety and lack of standardisation in cardiovascular outcome 
reporting in trials of people on haemodialysis.  I have identified and achieved 
consensus on using myocardial infarction and sudden cardiac death as core measures 
of CVD important to all stakeholders.  These are critical steps in the process of defining 
a CVD core outcome set for use in trials of people on haemodialysis.  
 
Future Work 
I will be conducting an Expert Working Group discussion at The American Society of 
Nephrology Kidney Week 2019 to produce a standardised definition of myocardial 
infarction for use in trials in people on haemodialysis.  The Expert Working group 
consists of patients, nephrologists, cardiologists, regulatory bodies and biomarker 
specialists.  Once the definition of myocardial infarction is standardised for this 
population we will aim to design and perform a study to validate this definition in the 
haemodialysis population.  If appropriately validated, this definition of MI will be able 
to be used as a core measure of CVD in all trials in people on haemodialysis.  
 
Epidemiology of cardiac disease in the ESKD population 
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Significantly higher rates of cardiovascular disease remain in the ESKD population 
compared to the general population and patterns in the epidemiology do not mirror 
the general population.    The discrepancy between the improvements seen in the 
cardiac mortality rate in ESKD and the lack of improvements in cardiac event rate may 
be explained by the improvements in the treatment of these events. It also  highlights 
potentially ineffective primary preventative strategies. Recognition of the sex 
discrepancies between the ESKD population and the general population generates 
hypotheses with regard to the pathophysiology of CVD in ESKD, the access to care and 
management of CVD in women with ESKD.  
 
Future Work 
I am continuing to explore the linked data to examine potential risk factors for cardiac 
mortality, the differences in cardiac mortality rates between different renal 
replacement therapy modalities and the impact of transplant on cardiac mortality 
rates.  My work to date has highlighted the sex differences in the ESKD population and 
I intend to explore the reasons for the differences including access to treatment, 
provision of preventative and treatment strategies and the potential of excess harms 
in the use of current treatments. 
 
Cognition in people with ESKD 
I have identified specific patterns of cognitive deficits in people with ESKD, particularly 
in orientation and attention and in executive function.  Much of the education 
provided to patients with ESKD is offered at or near the onset of ESKD when it is likely 
that these cognitive deficits are already apparent.  Education is also often provided 
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through extended educational programs lasting a number of hours.  This work should 
inform the design of future education programs for people on haemodialysis, 
potentially with a focus on shorter and more frequent education sessions to account 
for the attention deficits.  These cognitive deficits are also critical for consideration by 
clinicians in shared clinical decision-making and promoting self-management of this 
chronic disease.  The comparison of cognitive deficits in ESKD and the general 
population may inform hypotheses on the involvement of cerebrovascular disease in 
the development of cognitive impairment in ESKD. 
 
Future Work 
One of the challenges presented in performing the meta-analysis of trials assessing 
cognition was the lack of standardisation in the use of cognitive tests to assess the 
individual cognitive domains.  I am in the process of performing a similar meta-analysis 
focussing on the cognitive impairments in people on peritoneal dialysis.  Using meta-
analyses performed across the spectrum of kidney disease we intend to summarise, 
evaluate and rank the cognitive tests that are most suitable for use in the assessment 
of cognitive impairment in people with ESKD.   
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Figure 1 Example schema for categorization of original definitions into the final outcome group 
  
Abbreviations: ACS – acute coronary syndrome, MI – myocardial infarction 
Original definitions 
Outcome 
measures 
 (based on 
similarity) 
Outcome 
group 
Acute coronary syndrome, number of  
myocardial infarctions, Non-fatal 
myocardial infarctions, incidence of MI, 
time to MI, time without MI, Acute MI 
MI&ACS 
 
Myocardial 
infarction  
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Figure 2  Measures and time points within the cardiovascular composite outcome. 
Bar chart to show the proportion of trials reporting each measure within the 
Cardiovascular composite outcome, as well as the time points at which they are 
reported 
 
Time points reported as dots and % trials reporting outcome measure in bars.
 
  
 
 
 
  
 Appendix 1: Supplementary data for Chapter 2 
183 
 
Figure 3 Proportion of trials reporting CVD mortality outcome 
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Table 1 Search strategy 
Database Number Search term 
Medline 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
1 Renal Replacement Therapy/ 
2 Renal Dialysis/ 
3 Hemodiafiltration/ 
4 Haemodialysis, home/ 
5 exp Hemofiltration/ 
6 dialysis.tw. 
7 (haemodialysis or haemodialysis).tw. 
8 (hemofiltration or haemofiltration).tw. 
9 (hemodiafiltration or haemodiafiltration).tw. 
10 or/1-9 
11 randomized controlled trial.pt. 
12 10 and 11 
13 limit 12 to yr="2011 -Current" 
14 exp Cardiovascular Diseases/ 
15 exp Cerebrovascular Circulation/ or exp Cerebrovascular Disorders/ 
16 exp Myocardial Revascularization/ or exp Myocardial Ischemia/ or exp Myocardial Infarction/ 
17 14 or 15 or 16 
18 13 and 17 
19 exp Coronary Disease/ or exp Atherosclerosis/ 
20 exp Stroke/ 
21 exp Vascular Diseases/ 
22 14 or 15 or 16 or 19 or 20 or 21 
23 13 and 22 
24 exp Mortality/ 
25 22 or 24 
26 13 and 25 
27 clinical trial.pt. or randomized.ab. or placebo.ab. or dt.fs. or randomly.ab. or trial.ab. or groups.ab. 
28 10 and 22 
29 10 and 25 
30 27 and 29 
31 limit 30 to yr="2011 -Current" 
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32 limit 31 to ("all adult (19 plus years)" and humans) 
Embase 
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
  
1 haemodialysis/ 
2 dialysis membrane/ or dialysis catheter/ or dialysis pump/ or home dialysis/ or dialysis/ or dialysis.mp. or extended daily dialysis/ or equilibrium dialysis/ or 
          3 haemodialysis.mp. or haemodialysis/ 
4 hemofiltration/ or continuous hemofiltration/ or hemofiltration.mp. 
5 hemodiafiltration/ or continuous hemodiafiltration/ or hemodiafiltration.mp. 
6 exp mortality/ or exp hemofiltration/ or exp haemodialysis/ or exp renal replacement therapy/ 
7 1 or 2 or 3 or 4 or 5 or 6 
8 cardiovascular.mp. or interventional cardiovascular procedure/ or cardiovascular risk/ or cardiovascular equipment/ or cardiovascular system/ or 
               
                
                  
                
                  
              
9 exp cerebrovascular disease/ or exp occlusive cerebrovascular disease/ or exp cerebrovascular accident/ or exp cerebrovascular surgery/ 
10 cardiac.mp. 
11 exp peripheral occlusive artery disease/ or exp peripheral circulation/ or exp peripheral vascular system/ or exp peripheral vascular disease/ or exp peripheral 
 12 exp cardiovascular mortality/ or exp mortality/ 
13 exp atherosclerosis/ or exp coronary artery atherosclerosis/ or exp aorta atherosclerosis/ or exp carotid atherosclerosis/ or exp brain atherosclerosis/ 
14 exp heart/ 
15 stroke.mp. 
16 8 or 9 or 10 or 11 or 12 or 13 or 14 or 15 
17 7 and 16 
18 limit 17 to (randomized controlled trial and yr="2011") 
19 limit 18 to human 
20 limit 19 to adult <18 to 64 years> 
21 limit 19 to aged <65+ years>  
22 20 or 21 
Clinicaltrials.gov 
  
1 haemodialysis 
2 cardiovascular  
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Table 2 Original definitions and categorized outcome measures allocated to the cardiovascular composite outcome. 
Trial 
 
Original Outcome definition Measure 
7 Time to atherosclerotic cardiac event Atherosclerotic Event 
60 Total: any major atherosclerotic event Atherosclerotic Event 
12 Fatal and nonfatal CHD (MI, PTCA, CABG) CHD Event 
12 Non-fatal coronary heart disease CHD Non Fatal 
199 Coronary artery disease Coronary Artery Disease 
60 Any major coronary event Coronary Event 
3 Time to the occurrence of a combined end-point consisting of new onset of documented acute myocardial infarction, 
       
CV Composite 
3 Time to the occurrence of a combined end-point consisting of new onset of documented acute myocardial infarction, 
             
CV Composite 
6 The cumulate rate of non fatal MI or acute coronary syndrome, hospitalization for heart failure, nonfatal stroke or CV 
 
CV Composite 
6 The time of survival without a major CV event (non fatal MI, acute coronary syndrome, hospitalization for heart failure, 
     
CV Composite 
6 The time to onset of the first incident :non-fatal MI or acute coronary syndrome or hospitalization for heart failure or 
      
CV Composite 
6 The cumulate rate of non fatal MI or acute coronary syndrome, hospitalization for heart failure, nonfatal stroke or CV 
 
CV Composite 
7 Major adverse cardiac events (non fatal MI, non fatal stroke, death from cardiovasc cause) CV Composite 
7 Time to first cardiac event (combined endpoint of cardiac death and nonfatal myocardial infarction) CV Composite 
12 Fatal and nonfatal cardiovascular events CV Composite 
19 Time to death or the first nonfatal cardiovascular event (myocardial infarction, hospitalization for unstable angina, 
       
CV Composite 
22 Deaths and major cardiovascular events CV Composite 
26 Cumulative incidence of the composite outcome "death, myocardial infarction, heart failure". CV Composite 
31 Major cardiovascular event (fatal or non fatal cardiac event such as cardiac arrest, heart failure, myocardial infarction, 
           
CV Composite 
51 Composite of death, nonfatal stroke, nonfatal myocardial infarction and coronary revascularization CV Composite 
57 Composite of major cardiovascular events (hospitalised myocardial infarction, hospitalised stroke, coronary artery or 
  
CV Composite 
57 Major cardiovascular events (as above), all-cause death and hospitalized heart failure CV Composite 
60 Major vascular events  (ie, major atherosclerotic events plus non-coronary, cardiac deaths and haemorrhagic strokes: CV Composite 
77 Major adverse cardiovascular events (Death, non-fatal myocardial infarction and stroke) CV Composite 
78 Death or hospitalisation from cardio- and cerebrovascular causes (CCV events included new occurrence or exacerbation 
                 
             
           
              
              
              
              
                 
CV Composite 
85 Symptom-driven coronary revascularization and death from cardiovascular cause CV Composite 
95 Fatal and non fatal CV events (MI, stroke, unstable angina, revasc) CV Composite 
98 Cardiovascular disease defined as a composite of the following outcomes: fatal and non-fatal myocardial infarction (MI), 
       
CV Composite 
155 Any CV event + CV death CV Composite 
155 Any CV event + death of any cause CV Composite 
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156 MACE CV Composite 
156 Major adverse cardiovascular events: myocardial infarction, stroke, acute coronary syndrome,embolism, symptom-
             
CV Composite 
167 The main outcome variable will be a combined end-point of cardiovascular death (including sudden death and cardiac 
  
CV Composite 
167 The main outcome variable will be a combined end-point of cardiovascular death (including sudden death and cardiac 
       
CV Composite 
171 All cause and cardiovascular mortality CV Composite 
174 The primary endpoint is composite of :1) cardiovascular death 2)sudden cardiac death 3)nonfatal myocardial infarction 
       
CV Composite 
182 Treatment-emergent events - combined incidence of death, myocardial infarction, stroke, hospitalizations, potassium 
        
CV Composite 
184 Cumulative incidence of the composite outcome "death, myocardial infarction, heart failure" CV Composite 
188 Composite outcome of all-cause mortality or major cardiovascular event rate CV Composite 
188 Rate for the composite outcome of all-cause mortality or hospitalization for ischemic stroke, myocardial infarction, or 
          
CV Composite 
192 Time to first occurrence of an event in the primary composite outcome composite of major cardiovascular events 
           
  
CV Composite 
192 |Time to first occurrence of an event in the secondary composite outcome  major cardiovascular events (hospitalised 
            
   
CV Composite 
195 Time to first occurrence of adjudicated MACE CV Composite 
195 Time to the first occurrence of adjudicated major adverse cardiovascular event (MACE) (composite of all-cause 
        
CV Composite 
195 Time to first occurrence of adjudicated MACE or a hospitalization for heart failure (HF) CV Composite 
195 Time to first occurrence of adjudicated MACE or a thromboembolic event (vascular access thrombosis, deep vein 
    
CV Composite 
197 Cardiovascular event free survival time Cardiovascular event consisting of death due to cardiovascular diseases 
             
           
CV Composite 
198 Cardiovascular disease CV Disease 
12 Nonfatal cardiovascular disease (first event) CV Disease Non Fatal 
1 All cardiac events CV Event 
1 Combined cardiovascular events CV Event 
6 The time of survival without a major CV event (non fatal MI, acute coronary syndrome, hospitalization for heart failure, 
     
CV Event 
11 Composite cardiovascular events CV Event 
12 Cardio- and cerebrovascular events CV Event 
14 Cardiovascular event CV Event 
17 Cardiovascular events CV Event 
23 Cardiovascular events CV Event 
31 Cardiovascular event free survival CV Event 
38 Cardiovascular events (adv events) CV Event 
44 Major adverse cardiac events CV Event 
51 CVD CV Event 
53 Cardiovascular serious adverse events in each arm of treatment. CV Event 
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54 Cardiovascular events CV Event 
68 Cardiovascular events CV Event 
71 The Occurrence of Cardiovascular Event CV Event 
76 Incidence of Composite Cardiovascular Events CV Event 
82 Cardio-cerebral event CV Event 
121 Cardiovascular/stroke CV Event 
146 Cardiovascular events CV Event 
165 Cardiovascular event rate: events per 1,000 access CV Event 
165 One cardiovascular event CV Event 
165 Cardiovascular event-free CV Event 
170 Rate of cardiovascular events CV Event 
171 Incidence of cardiovascular events CV Event 
172 Composite endpoints cardiovascular event CV Event 
173 Major CVD events CV Event 
12 Non fatal cardiovascular event CV Event Non Fatal 
51 Non-fatal non outcome CVD CV Event Non Fatal 
95 Non fatal CV event CV Event Non Fatal 
98 First cardiovascular event non fatal(myocardial infarction hospitalization for unstable angina heart failure or periph vasc 
 
CV Event Non Fatal 
24 Cardiovascular hospitalization (defined as hospitalization for ischemic heart disease, heart failure, arrhythmias, other 
       
CV Hospitalisation 
100 Cardiovascular disease hospitalisation CV Hospitalisation 
184 All-cause and cardiovascular hospitalization. CV Hospitalisation 
28 Cardiovascular morbidity CV Morbidity 
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Table 3 Subgroup analysis: number of measures reported per trial by size of trial 
    Number of measures 
No of Participants No of trials Median  IQR Range 
<=100 99 3 1.0-6.5 1-18 
>100 to <=500 47 4 1.5-6.0 1-17 
>500 to <=5000 19 5 1.5-10 1-23 
>5000 2 6 6.0-6.0 6-6 
Missing 7 1 1.0-6.0 1-6 
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Figure 1 Data linkage process 
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Table 1 ICD Codes of interest* 
ICD10  ICD 10 Class ICD 10 Description ICD9 Code ICD 9 Description 
Ischaemic heart disease    
I20 I20-I25   Ischaemic Heart Diseases I20  Angina Pectoris                                                                                                                                                                                     413 413  Angina Pectoris                                                                                           
I21 I20-I25   Ischaemic Heart Diseases I21  Acute Myocardial Infarction                                                                                                                                                                         410 410  Acute Myocardial Infarction                                                                               
I22 I20-I25   Ischaemic Heart Diseases I22  Subsequent Myocardial Infarction                                                                                                                                                                    (Also 410)
I24 I20-I25   Ischaemic Heart Diseases I24  Other Acute Ischaemic Heart Diseases                                                                                                                                                                411 411 Other Acute & Subacute Forms Of Ihd                
I25 I20-I25   Ischaemic Heart Diseases I25  Chronic Ischaemic Heart Disease                                                                                                                                                                     414 414 Other Forms Of Chronic Ihd                                  
Valve disease    
I34 I30-I52  Other Forms Of Heart Disease   I34  Nonrheumatic Mitral Valve Disorders                                                                                                                                                                 424 424  Other Diseases Of Endocardium                                  
I35 I30-I52  Other Forms Of Heart Disease   I35  Nonrheumatic Aortic Valve Disorders                                                                                                                                                                 
I36 I30-I52  Other Forms Of Heart Disease   I36  Nonrheumatic Tricuspid Valve Disorders                                                                                                                                                              
I37 I30-I52  Other Forms Of Heart Disease I37 Nonrheumatic Pulmonary valve disorders   
Cardiomyopathy    
I42 I30-I52  Other Forms Of Heart Disease   I42  Cardiomyopathy                                                                                                                                                                                      425 425  Cardiomyopathy                                                                                           
Arrhythmia    
I44 I30-I52  Other Forms Of Heart Disease   I44  Atrioventricular And Left Bundle-Branch Block                                                                                                                                                       426 426 Conduction Disorders                              
I45 I30-I52  Other Forms Of Heart Disease   I45  Other Conduction Disorders                                                                                                                                                                          
I46 I30-I52  Other Forms Of Heart Disease   I46  Cardiac Arrest                                                                                                                                                                                      427.5 (427.5 Cardiac Arrest ) 
I47 I30-I52  Other Forms Of Heart Disease   I47  Paroxysmal Tachycardia                                                                                                                                                                              427 427  Cardiac Dysrhythmias (Approximate)                                                                                    
I48 I30-I52  Other Forms Of Heart Disease   I48  Atrial Fibrillation And Flutter                                                                                                                                                                     (Also 427) 
I49 I30-I52  Other Forms Of Heart Disease   I49  Other Cardiac Arrhythmias                                                                                                                                                                           (Also 427)
Heart Failure    
I50 I30-I52  Other Forms Of Heart Disease   I50  Heart Failure                                                                                                                                                                                       428 428 Heart Failure                                                                                            
*https://www.who.int/classifications/icd/icdonlineversions/en/  
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Table 2  The top ten underlying causes of death (as grouped by the leading 
  causes of death defined by the Australian Institute of Health and  
  Welfare 
Underlying cause of death Frequency Percent 
1 Diabetes 2,140 27.66 
2 Kidney failure 1,725 22.29 
3 Hypertensive disease 266 3.44 
4 Renal tubulo-interstitial disease 243 3.14 
5 Glomerular disease 210 2.71 
6 Septicaemia 208 2.69 
7 
Diseases of the musculoskeletal system and 
connective tissue  
150 1.94 
8 
Other diseases of intestines excluding paralytic 
ileus and intestinal obstruction without hernia  
142 1.84 
9 
Certain conditions originating in the perinatal 
period, congenital malformations, deformations 
and chromosomal abnormalities  
141 1.82 
10 
Diseases of arteries, arterioles and capillaries 
excl. atherosclerosis, aortic aneurysm and 
dissection  
131 1.69 
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Table 1 Search Strategy 
1. Cognition disorders/ 
2. Mild Cognitive Impairment/ 
3. Dementia/ 
4. exp Aphasia, Primary Progressive/ 
5. exp Dementia, Vascular/ 
6. Diffuse Neurofibrillary Tangles with 
Calcification/ 
7. exp Frontotemporal Lobar 
Degeneration/ 
8. (cognit* adj3 (impair* or disorder* or 
def*)).tw. 
9. dement*.tw. 
10. aphasi*.tw. 
11. (fronto?temporal lob* or 
fronto?temporal dement*).tw. 
12. diffuse neuro?fibrillary tangles with 
calcification.tw. 
13. or/1-12 
14. exp Renal Replacement Therapy/ 
15. h?emo?dialysis.tw. 
16. h?emo?filtration.tw. 
17. h?emo?diafiltration.tw. 
18. dialysis.tw. 
19. (CAPD or CCPD or APD).tw. 
20. (kidney transplant* or renal 
transplant* or kidney graft* or renal 
graft*).tw. 
21. Renal Insufficiency/ 
22. exp Renal Insufficiency, Chronic/ 
23. exp Kidney Diseases/ 
24. Uremia/ 
25. (kidney disease* or renal disease* 
or kidney failure or renal failure).tw. 
26. (ESRF or ESKF or ESRD or ESKD).tw. 
27. (CKF or CKD or CRF or CRD).tw. 
28. (predialysis or pre-dialysis).tw. 
29. ur?emi$.tw. 
30. or/14-29 
31. and/13,30 
32. exp Neuropsychological Tests/ 
33. Language Tests/ 
34. mini mental state exam*.tw. 
35. frontal assessment battery.tw. 
36. (wechsler adj3 (intelligen* or 
memory)).tw. 
37. (span adj2 (digit or spatial or 
symbol)).tw. 
38. matrix reasoning.tw. 
39. (clock drawing adj2 (test or 
task)).tw. 
40. halstead reitan battery.tw. 
41. trail making test.tw. 
42. tactual performance test.tw. 
43. block design test.tw. 
44. letter number sequencing test.tw. 
45. finger tapping test.tw. 
46. (reitan adj4 (test or task or 
exam*)).tw. 
47. token test.tw. 
48. boston naming test.tw. 
49. stroop test.tw. 
50. (word adj2 (rec* or list or associat* 
or context) adj2 (test or task or 
exam*)).tw. 
51. (picture adj2 (completion or 
recognition or presentation)).tw. 
52. (fluency adj2 (verbal or design or 
animal or lexical) adj3 (test or task or 
exam*)).tw. 
53. (memory adj3 (spatial or numeric or 
working) adj3 (test or task or 
exam*)).tw. 
54. stockings of cambridge.tw. 
55. rey osterrieth complex figure 
test.tw. 
56. buschke selective reminding 
test.tw. 
57. wisconsin card sorting test.tw. 
58. progressive matri*.tw. 
59. cognitive assessment screening.tw. 
60. ((simple or choice) adj3 reaction 
adj3 (speed or time)).tw. 
61. progressive matri*.tw. 
62. hooper visual.tw. 
63. "visual object and space perception 
battery".tw. 
64. (neuropsychiatric adj (inventory or 
battery)).tw. 
65. neuropsychological test*.tw. 
66. (3MS or PASAT or WASI or 
WAIS).tw. 
 Appendix 4: Supplementary data for Chapter 7 
198 
 
67. or/32-66 
68. and/31,67 
69. executive function/ 
70. memory/ 
71. language/ 
72. attention/ 
73. memory, long-term/ 
74. memory, short-term/ 
75. memory, episodic/ 
76. visual perception/ 
77. space perception/ 
78. psychomotor performance/ 
79. motor skills/ 
80. "task performance and analysis"/ 
81. global cognitive function*.tw. 
82. executive function*.tw. 
83. (memory adj3 (disorder* or 
function* or def*)).tw. 
84. (language adj3 (function* or 
disorder* or def*)).tw. 
85. ((attention or concentration) adj3 
(def* or disorder* or function*)).tw. 
86. ((visual or spatial or visualspatial or 
visuospatial) adj3 (function* or abilit* 
or awareness)).tw. 
87. (mental adj3 (efficien* or 
automatation or fluency) adj3 (def* or 
disorder* or function*)).tw. 
88. intelligence/ 
89. (intelligence adj3 (quotient or def* 
or abilit*)).tw. 
90. ((motor or psychomotor) adj3 
(abilit* or function* or def*)).tw. 
91. or/69-90 
92. and/30,91 
93. or/31,68,92 
94. remove duplicates from 93 
95. limit 94 to humans 
96. from 95 keep 1-1000 
97. from 95 keep 1001-2000 
98. from 95 keep 2001-2296 
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Table 2  Characteristics of studies meeting inclusion criteria, but without data that could contribute to meta-analysis 
Author Country 
Total 
(n) Study Design % Men 
Mean age (yrs) 
(SD/range) Reason for not contributing 
Brady 2009 USA 659 RCT 98.3 63.7(11.7) Data for CKD and HD not presented separately 
Groothoff 
2002 Netherlands 162 Cohort unknown 
29.4(20.7-
41.8) Data for groups not presented separately 
Kang 2012 America 169 Cross sectional 65.1 52.6(14.6) 
Data for CKD and HD patients not presented 
separately 
Morosanu 
2011 Romania 92 Cross sectional  unknown 72.1(5.9) Data presented not suitable for meta-analysis 
Tryc 2011 Germany 101 Cross sectional 47.5 51.0(12.9) Data presented not suitable for meta-analysis 
Tiffin-Richards 
2014 Germany 85 Cross sectional 52.9 58 Data presented not suitable for meta-analysis 
Afsar 2014 Turkey 174 Cross sectional 45.4 52.2 (16.3) 
Data for HD, CKD and gen pop not presented 
separately  
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Figure  1 Sources of heterogeneity.  
 
P values for interaction are for high versus low risk of bias (ROB), pre and post 1995, controls classified 
as healthy and other (which included controls taken from other primary care clinics).  
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First author publications during the course of the PhD but not included in the thesis: 
 
1. Barriers to the Professional Advancement of Women in Nephrology.  O'Lone E, 
Webster AC.   Clin J Am Soc Nephrol. 2019 Sep 6;14(9):1399-1401. PMID: 
31350274 
2. Parenteral versus oral iron therapy for adults and children with chronic kidney 
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3. Implementing core outcomes in kidney disease: report of the Standardized 
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Wang AYM, Hemmelgarn B, Wheeler DC, Gill J, Tugwell P, Pecoits-Filho R, 
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manuscript. 
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